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Overview of Dopamine and the Dopaminergic System 
 The neurotransmitter dopamine (3,4-dihydroxyphenethylamine, DA) 
makes a significant contribution to brain function through its modulatory role in 
pathways controlling reward, locomotor activity, and attention (Carlsson, 1987, 
Robbins, 2003). DA is synthesized in a two-step process involving first, the 
hydroxylation of tyrosine by tyrosine hydroxylase (TH) to yield L-
dihydroxyphenylalanine (L-DOPA) that is subsequently decarboxylated by L-
aromatic amino acid decarboxylase (AADC) to yield DA. The action of TH is rate-
limiting in this reaction due to the higher turnover rate and lack of substrate 
saturation of AADC. In pathways that utilize DA as a neurotransmitter, DA is 
packaged for release or processed further intracellularly to synaptically inactive 
metabolites.  DA is packaged for release into synaptic vesicles using vesicular 
monoamine transporter-2 (VMAT-2). DA is transported into the synaptic vesicles 
using proton gradient present across the synaptic vesicle membrane. VMAT-2 
function and expression is often altered by use of psychostimulants (Little et al., 
2003). Another VMAT isoform, VMAT-1, is mostly associated with large secretary 
granule vesicles, whereas VMAT-2 is predominantly present on small synaptic 
vesicles (Henry et al., 1994). In most brain regions, including striatum, free 
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intracellular DA is enzymatically degraded by isoforms of monoamine oxidase 
(MAO) into 3,4-dihydroxyphenylacetic acid (Jonason, 1969). In the prefrontal 
cortex, however, enzymatic breakdown of DA occurs by catechol-O-methyl 
transferase (COMT) into 3-methoxytyramine (Yavich et al., 2007). Other brain 
and peripheral pathways use DA as a precursor to produce norepinephrine (NE) 
and epinephrine.  Synthesis and degradation of DA is summarized in Figure 1.  
  	   Four major brain pathways utilize DA as a neurotransmitter: the 
tuberoinfundibular pathway, the nigrostriatal pathway, the mesocortical pathway, 
and the mesolimbic pathway (Figure 2). The tuberoinfundibular pathway 
originates from of neurons in the hypothalamic arcuate nucleus and projects to 
Figure 1 Biosynthesis and Degradation of Dopamine: (A) Biosynthesis of DA from the actions 
of enzymes, tyrosine hydroxylase, and dihydroxyphenylanine (DOPA) decarboxylase (also known 
as AADC due to its lack of specificity for DA). (B) Degradation of DA by monoamine oxidase and 
catechol-O-methyl transferase. 
	   3	  
the median eminence, where DA secretion produces prolactin secretion from the 
anterior pituitary gland. The nigrostriatal pathway, which modulates movement, 
and that is lost in Parkinson's disease, originates in neurons of the substantia 
nigra (SN), so named for their pigmented appearance in unstained sections. 
Dopaminergic (DAergic) axons from the SN terminate in nuclei of the basal 
ganglia, termed the striatum in rodents, but divided into the caudate nuclei and 
putamen in primates. Both the mesocortical and the mesolimbic pathways 
originate in the ventral tagmental area (VTA), projecting to the prefrontal cortex 
and nucleus accumbens, respectively. The mesocortical pathway is important in 
the modulation of motivation and emotion, whereas the mesolimbic pathway is 
implicated in reward and pleasure.	  
Figure 2 Schematic Illustration of Dopaminergic Projections: DA neurons in the VTA project 
to the nucleus accumbens and prefrontal cortex through the mesolimbic and mesocortical 
pathways, respectively. DA neurons in the SN project to the striatum via the nigrostriatal pathway. 
The tuberoinfundibular pathway is not depicted.  Adapted from Neuroanatomy, An Atlas of 
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 Due to the actions of DA in the regulation of motor and cognitive function, 
as well as the recognition of incentive salience and reward, alterations in DAergic 
tone can lead to multiple neurological and psychiatric disorders. These include 
Parkinsonʼs disease (Chase et al., 1998), dystonia (Kurian et al., 2009), 
attention-deficit hyperactivity disorder (ADHD) (Mazei-Robison et al., 2005), 
addiction (Ritz et al., 1987), and schizophrenia (Horn and Snyder, 1971). 
The first evidence for altered DA neurotransmission in a brain disorder 
involved the demonstration that rats given reserpine displayed features of 
Parkinsonʼs disease (Carlsson et al., 1966), findings that would ultimately bring 
Arvid Carlsson the Nobel Prize in 2000. Subsequently, Hornykiewicz established 
a loss of DA in the brains of Parkinson disease subjects (Ehringer and 
Hornykiewicz, 1960). The reversal of Parkinsonian symptoms by the DA 
precursor, L-DOPA, provided clear evidence of the role of DA in the disorder 
(Birkmayer and Hornykiewicz, 1962). Hornykiewicz would go on to show that 
Parkinsonʼs disease arises from degeneration of nigrostriatal DA neurons, 
resulting in denervation of basal ganglia that form the extrapyramidal motor 
system (Hornykiewicz, 1972).  
 Although Parkinsonʼs disease patients, particularly in the latter stages, 
often exhibit cognitive and emotional problems, the idea that DAergic dysfunction 
is involved in psychiatric disorders derives in large measure from research 
demonstrating altered DA metabolism and signaling in patients with 
schizophrenia (Hokfelt et al., 1974, Lindvall et al., 1974). Indeed, classical 
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antipsychotic drugs, including chlorpromazine and haloperidol, block D2 subtype 
DA receptors, thus suggesting a role for hyperdopaminergic signaling (Horn and 
Snyder, 1971). Another strong evidence of altered DAergic neurotransmission 
contributing to a neuropsychiatric disorder came from ADHD patients. ADHD is 
the most commonly diagnosed childhood disorder affecting 3-5% of school age 
children. Multiple studies point to a contribution of variation in genes expressed in 
DAergic neurons as influencing risk for ADHD (Gill et al., 1997, Qian et al., 2003, 
Bobb et al., 2005, Mazei-Robison et al., 2005). I will discuss relationship between 
ADHD and DAergic transmission later in this chapter. Whereas L-DOPA and 
chlorpromazine have therapeutic efficacy, other drugs targeting DA signaling can 
be highly addictive, including the psychostimulants cocaine and amphetamine 
(AMPH), Long-term use of these agents produces molecular, cellular and circuit-
level plasticities that drive a desire and search for drug, despite the recognition of 
negative consequences (Kauer and Malenka, 2007, Dietz et al., 2009). Taken 
together, alterations in DA signaling can be seen to underlie multiple, devastating 
disorders that affect tens of millions of individuals worldwide. My thesis research 
derives from the belief that a better understanding of DA signaling mechanisms, 
and how these mechanisms are perturbed by disease states, can lead to 
advances in the prevention, diagnosis and therapy.  	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Discovery of Presynaptic DA Transport and Demonstration of Specific DA 
Transporter (DAT) Binding Sites 	  
 Acetylcholine, the first identified neurotransmitter, is inactivated by 
degradation via the extracellular enzyme acetylcholinesterase (AChE). Although 
metabolism of the catecholamine NE by MAO and COMT to inactive products 
has been established, acute inhibition of these enzymes does not impact 
synaptic DA inactivation.  Axelrod and colleagues discovered that radiolabeled 
NE could be sequestered into the terminals of sympathetic neurons (Hertting and 
Axelrod, 1961), and subsequently demonstrated that NE accumulation could be 
blocked by both antidepressants and psychostimulants (Axelrod et al., 1961, 
Hertting et al., 1961). These studies lead to the hypothesis that synaptic NE 
inactivation was mediated by rapid clearance through a presynaptic uptake 
process (Axelrod, 1971). Later, investigators would demonstrate that brain slices 
could accumulate both NE and DA and that psychostimulants could inhibit this 
process (Carlsson et al., 1966, Glowinski and Axelrod, 1966, Ross and Renyi, 
1967). Subsequently, Ross and Renyi demonstrated that the pharmacological 
profiles of DA uptake inhibition in striatum and cortex were distinct from that of 
NE uptake inhibition (Ross and Renyi, 1967). They demonstrated that whereas 
AMPH and cocaine were potent inhibitors of DA and NE uptake in both brain 
regions, desipramine was a weak inhibitor of DA uptake in striatum, but a potent 
inhibitor of NE in cortex (Ross and Renyi, 1967). These findings suggested that 
the DA uptake mechanism was distinct from that supporting NE clearance, 
	   7	  
contributing further to the idea that DA was not simply a precursor for NE but also 
a neurotransmitter in its own right. Snyder and Coyle would go on to demonstrate 
that the specificities of the DA and NE uptake processes for isomers of AMPH 
were distinct (DA uptake equivalently inhibited by D- and L-AMPH, NE uptake 
preferentially inhibited by D-AMPH) (Snyder and Coyle, 1969). Ritz and 
coworkers provided further dissociation of the actions of cocaine on DA and NE 
uptake sites by demonstrating cocaineʼs potency to inhibit DA uptake in rat brain 
extracts was significantly higher than cocaineʼs potency for inhibiting NE uptake 
(Ritz et al., 1987). Ritz and colleagues also reported important in vitro findings 
that the antagonist potency in blocking brain DA uptake correlated well with the 
potency of cocaine determined from self-administration studies with non-human 
primates (Ritz et al., 1987), further strengthening the hypothesis that the abuse 
liability of the psychostimulant derived from an inhibition of DA transport and 
inactivation.  
 The studies described above prompted efforts to identify the DA 
transporter, first by demonstrating the presence of specific cocaine binding sites 
in brain and their relationship to the DA reuptake process. Autoradiographic 
studies using the cocaine analog [3H] 2 beta-carbomethoxy-3 beta-(4-
fluorophenyl)tropane ([3H]CFT) demonstrated specific binding presence in 
monkey brain, specifically in the caudate and putamen, a dopamine-rich area, 
and one that had been previously implicated in the behavioral effects and abuse 
potential of cocaine (Canfield et al., 1990). Kennedy and Hanbauer, using rat 
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striatal synaptosomes, demonstrated the presence of presynaptic, Na+-
dependent cocaine binding sites (Kennedy and Hanbauer, 1983). Today, these 
cocaine binding sites are known to reflect the presence of DAT protein. Such 
binding approaches remain valuable as they are used with in vitro studies of DAT 
regulation as well as for in vivo analyses, as with positron emission tomography 
(PET) imaging techniques to monitor DAergic nerve terminals in Parkinsonʼs 
disease (Antonini et al., 2001, Song et al., 2012). 
  
Cloning of DAT cDNAs 
In 1988, Blakely and colleagues demonstrated the transport of 
radiolabeled L-glutamate, gamma-aminobutyric acid (GABA), glycine, DA, 
serotonin (5-HT), and choline in Xenopus laevis oocytes microinjected with brain 
mRNAs. mRNAs competent for expression of neurotransmitter transporter 
demonstrated a regional enrichment consistent with the anatomical distribution of 
neurotransmitter synthesizing soma and thereby demonstrated the opportunity 
for expression cloning of neurotransmitter transporter proteins (Blakely et al., 
1988).  Following the cloning of the norepinephrine (NET) (Pacholczyk et al., 
1991) and serotonin transporters (SERT) (Blakely et al., 1991), four groups 
reported the cloning of cDNAs encoding rat and bovine DATs (Giros et al., 1991, 
Kilty et al., 1991, Shimada et al., 1991, Usdin et al., 1991). Using in situ 
hybridization, several of these groups demonstrated that DAT mRNA was 
expressed in the SN and VTA, consistent with the localization of DA neuron cell 
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bodies (Giros et al., 1991, Kilty et al., 1991, Shimada et al., 1991). Heterologous 
expression of rat DAT cDNA revealed the induction of a Na+- and Cl- dependent, 
DA uptake process that was absent in non-transfected cells. The transport of DA 
displayed a high-affinity for DA, with a KM estimated at between 300 and 900 nM. 
Finally, the in vivo DA uptake blockers, GBR12909 (IC50=12 nM), mazindol 
(IC50=27 nM), cocaine (IC50=336 nM), and D-AMPH (IC50=881 nM) inhibited DA 
uptake (Giros et al., 1991) with the same potencies previously reported with rat 
brain synaptosomes (Ritz et al., 1987). Together, these studies validated the 
contention that the DAT transcript produced a protein with the properties 
expected for the DA uptake process, including its antagonist-binding site, in the 
CNS.  They also revealed that no additional, brain-specific subunits were 
required to produce functional DAT protein. 
 Oligonucleotides based on rat DAT cDNA sequence were used to design 
probes to clone human dopamine transporter (DAT) cDNA from SN libraries 
(Giros et al., 1992, Vandenbergh et al., 1992). DAT is now understood to be a 
620 amino acid protein that displays ~92% amino acid identity to rat DAT. DAT 
displays reduced, but significant identity to other members of the Na+/Cl--
dependent neurotransmitter transporter family (SLC6) members, with highest 
amino acid sequence identify observed with hNET (66%) and the human 
serotonin transporter (hSERT, 50%). Hydropathy analysis of DAT, like that of 
other SLC6 transporters, predicts 12 transmembrane domains (TMDs) with N- 
and C- termini located intracellularly (Figure 3). Three sites for N-linked 
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glycosylation are located in extracellular loop 2 (EL2) that connects TMDs 3 and 
4. Mutating all three canonical glycosylation sites as well as enzymatic 
degradation and blockade of glycosylation resulted in reduced DAT surface 
expression; significantly diminished catalytic activity and inhibitor sensitivity 
compared to wildtype (WT) DAT (Li et al., 2004).  Recently, a novel isoform of 
DAT produced by alternative splicing was discovered from human blood cells 
(Sogawa et al., 2010). The spliced isoform lacked exon 6, resulting in the deletion 
of TMD5 and an extracellular C-terminus. Further characterization showed 
expression differences between brain and peripheral tissues, indicating tissue-
specific, alternative splicing. Expression of the spliced isoform resulted in loss of 
DAT activity and when expressed with the WT DAT, the spliced isoform acted 
Figure 3. Schematic Illustration of the hDAT Topology: The hDAT protein 
contains 12 TMDs with N-and C-termini located intracellularly. Large EL2 
contains 3 N-linked glycosylation sites. There are numerous consensus 
phosphorylation sites depicted by P in black circle on the N-terminus.
Figure 3 Schematic Illustration of DAT Topology: The DAT protein contains 12 TMDs with N-
and C-termini located intracellularly. EL2 contai s 3 N-linked glycosylation sites. Numerous 
consensu  phosphorylation sites, depicted by P in a black circl , are found on the N- and C-
termini as well as intracellular loops. 
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dominantly, reducing overall DA uptake (Sogawa et al., 2010). The functional 
significance of these observations in vivo, however, is unknown. Additionally, in 
schizophrenia patients, Talkowaski and colleagues identified a novel cassette 
exon within intron 3 of DAT gene that is conserved among primates (Talkowski et 
al., 2010). The presence of this cassette exon introduces multiple in-frame stop 
codons resulting in a truncated product, and that may undergo nonsense-
mediated decay. The presence of this spliced variant was confirmed using RNA 
from postmortem human SN. Factors that increase use of this cassette exon 
splice variant could reduce the amount of unspliced RNA encoding WT DAT, with 
attendant functional consequences (Talkowski et al., 2010).  
 
Dopamine Transporter Structure and Function 
The characterization of DAT structure/function relationships has largely 
relied on heterologous expression studies performed in vitro. Data from studies 
expressing DAT and NET chimeras provided initial evidence that discrete 
domains within the transporter were involved in distinct functions such as 
substrate recognition, translocation, and affinity (Buck and Amara, 1994, Giros et 
al., 1994, Syringas et al., 2000). In these studies, TMDs 1-3 and 10-11 were 
identified as important for determining substrate affinity, whereas TMDs 5-8 were 
identified as critical for substrate translocation and the selectivity of inhibitors 
(Buck and Amara, 1994, Giros et al., 1994). Using similar approaches, TMDs 1-3 
	   12	  
and 9-12 were identified as important for the Na+ and Cl- dependence exhibited 
by DAT, as well as other SLC6 transporters (Syringas et al., 2000). 
Whereas chimera studies implicated broad regions of the transporter in 
key DAT properties, site-directed mutagenesis studies provided insights into 
more defined structure-function relationships, identifying in some cases single 
residues important for transport function and regulation. These studies indicated 
that, aside from support for N-glycosylation, EL2 appears to play a role, or be 
influenced by, inhibitor interactions, as inhibitor binding could be shown to protect 
DAT from trypsin digestion in this region (Gaffaney and Vaughan, 2004). In 
contrast, DAT substrates do not protect against proteolytic digestion (Gaffaney 
and Vaughan, 2004). Additionally, zinc immobilization of EL2 was shown to block 
DA transport through coordination of residues of EL2 and EL4, suggesting that 
movement of EL2 might be crucial for substrate translocation, possibly by 
structural movement of TMDs 3 and 4 (Norregaard et al., 1998). Interestingly, 
zinc immobilization of EL2 and EL4 increases ion conductance, which negatively 
impacts transport and stimulates efflux (Meinild et al., 2004). The later studies 
highlight the importance of electrophysiological approaches in providing 
mechanistic insights of mutation-induced changes in DAT function.       
To further our understanding as to how both substrates like DA and 
antagonists like cocaine interact with DAT, mutagenesis studies have been 
conducted to identify residues critical for ligand coordination. In these studies, 
alanine substitution was used to modify residues in or near TMDs, including all 
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tryptophan (Lin et al., 2000b), proline (Lin et al., 2000a), and phenylalanine (Lin 
et al., 1999) residues. The importance of Asp79 (Kitayama et al., 1992) and 
Phe105 (Wu and Gu, 2003) residues in cocaine recognition has been studied in 
detail. DAT immunogold labeling has shown that in the nigrostriatal neurons, 
these transporters are strategically localized to extrasynaptic plasma membrane 
to re-uptake diffused DA back into the presynaptic terminal (Nirenberg et al., 
1997). Using chemical cross-linkers, Fluorescent Resonance Energy Transfer 
(FRET) analysis, and expression studies with differentially tagged DAT 
constructs, DAT have been shown to exist in oligomeric form at the plasma 
membrane (Hastrup et al., 2001, Sorkina et al., 2003b). 
 Although the three dimensional structure of DAT is unknown, the 
generation of a high-resolution crystal structure for a bacterial SLC6 family 
member from Aquifex aeolicus, the leucine transporter (LeuTAa) supports the 
prediction of a 12 TM topology for DAT and homologs (Yamashita et al., 2005). 
The orientation and arrangement of TMDs of LeuTAa is depicted in Figure 4.  
Unfortunately the leucine transporter has short cytoplasmic N- and C-termini that 
are unstructured in the crystal structure. Molecular modeling efforts based on the 
information obtained from the crystal structure of LeuTAa helped Beuming and 
colleagues investigate the relationship between DA and cocaine binding sites on 
DAT (Beuming et al., 2008). Modeling and mutagenesis approaches provided 
evidence that the binding sites for cocaine and cocaine analogs are buried 
deeply between TMDs 1, 3, 6, and 8 and overlap with the binding site for DA and 
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AMPH (Beuming et al., 2008). Recently, using steered molecular dynamics 
simulation and homology modeling, a second DA binding site has been proposed 
to lie in the DAT extracellular vestibule and that this second substrate-binding site 
allosterically modulates transport mechanism (Shan et al., 2011). This proposal 
remains a significant point of debate among investigators studying the structural 
determinants of the function of SLC6 family members (Piscitelli et al., 2010).  
The cytosolic tails and intracellular loops of DAT contain numerous serine, 
and threonine residues, some of which are located in consensus sites for protein 
kinase C (PKC), protein kinase A (PKA), and calcium calmodulin-dependent 
kinase II (CaMKII). However, the exact residues phosphorylated by these 
kinases remains an active area of investigation (see below).  
Figure 4 Schematic Topology of DAT Based on LeuTaA crystal structure: TMDs1-5 and 6-
10 form a pseudo two-fold axis in the membrane plane (inverted triangle configuration) and fold 
over forming substrate translocation pathway. Yellow triangle with L and blue circles depict 
leucine and sodium ions respectively. TMDs 11 and 12 flank the outer surface of TMDs 9 and 10, 
and possibly contributing to the oligomerization. Adapted from Yamashita et al., 2005. 
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The transport of DA is Na+ and Cl- dependent, with a predicted 
stoichiometry of 2Na+, 1Cl- and one DA+ (DA is positively charged at 
physiological pH) (Amara and Kuhar, 1993). In keeping with the proposed net 
charge transfer per transport cycle, DA transport through DAT is electrogenic and 
a voltage dependent process, where hyperpolarization increases and 
depolarization decreases DA transport (Sonders et al., 1997). 
Electrophysiological studies reveal that DA transport through DAT produces a 
larger current than is expected for stoichiometric charge transfer determined by 
the ion-dependence of DA transport. This observation appears to reflect the 
presence of channel-like states that operate to permit ion permeation during the 
DA transport cycle (Carvelli et al., 2004, Kahlig et al., 2005).  
As a DAT substrate, AMPH competitively inhibits DA reuptake, causing an 
increase in synaptic DA that otherwise would have been cleared by re-uptake. 
Additionally, AMPH stimulates the release of DA through DAT in the brain 
(Fischer and Cho, 1979, Jones et al., 1998) and in transfected cells expressing 
DAT (Khoshbouei et al., 2003). AMPH-induced DA efflux has been considered to 
be mediated by a facilitated-exchange diffusion process, in which the inward 
transport of AMPH increases the availability of inward-facing binding sites of the 
transporter (Fischer and Cho, 1979), thereby leading to increased efflux of 
cytosolic DA. As noted below, this perspective is altogether too simple as multiple 
kinase-mediated signaling mechanisms can shift DAT into an “efflux willing” 
state. Finally, AMPH is a weak base and as a VMAT substrate, can collapse the 
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synaptic vesicle proton gradient needed for VMAT to package DA (Sulzer et al., 
1995). Via this process, AMPH can elevate cytoplasmic DA levels and enhance 
the probability of DAT-mediated DA efflux.  
 
Regulation of the Dopamine Transporter 
Although DAT was recognized early in its documentation as a target for 
psychoactive drugs, the transporter was discussed more as a static component 
of presynaptic homeostasis, inexorably clearing DA upon synaptic release. 
Mechanisms that could influence DAT activity and clearance were unknown. An 
early hint that DAT might be locally regulated arose from studies of Kuharʼs 
group, where irreversible inhibitor manipulation of striatal DAT revealed that the 
time for newly synthesized DAT to replace inactivated transporters in terminals is 
very long, on a synaptic transmission scale, with only ~50% of DAT replaced in 6 
days (Fleckenstein et al., 1996). Although later studies reduced this figure to 2-3 
days (Kimmel et al., 2000), the point remains that somatic biosynthetic 
mechanisms are too slow to effect significant changes in DAT-mediated DA 
clearance to match the more rapid changes in the firing rates of DA neurons 
(Goto et al., 2007). Today, evidence exits that rapid (sec-minutes) DAT regulation 
is imposed by presynaptic receptors, associated proteins and intracellular 
signaling networks, with evidence that both functional changes and/or membrane 
environment dictate the capacity for DA clearance (Zahniser and Doolen, 2001, 
Torres, 2006, Chen et al., 2010).  
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Presynaptic receptors 
DA acts on both post- and pre-synaptic receptors, with presynaptic D2 
receptors belonging to the Gi/Go family of G-protein coupled receptors (GPCR) 
that decrease adenylate cyclase activity (among other actions). D2 receptors 
have two isoforms as a result of alternative splicing with different spliced forms 
expressed pre or post-synaptically. D2 long (D2L) receptors, which have 
additional 29 amino acids in third intracellular loop and are exclusively expressed 
on postsynaptic neurons (Giros et al., 1989). On the other hand, D2 short (D2S) 
receptors that lack 29 amino acid insert are expressed presynaptically and act as 
DA autoreceptors. In response to elevated extracellular DA, D2S receptor provide 
inhibitory feedback in altering DA synthesis, release, and re-uptake (Meiergerd et 
al., 1993),  with DAT regulation mediated by initiation of a second messenger 
cascade (Meiergerd et al., 1993). D2S receptors have been reported to increase 
DAT activity through activation of extracellular signal-regulated kinases (ERK1 
and 2) (Bolan et al., 2007). The same group also provided evidence that D2S 
receptor modulation of DAT involves a phosphoinositide-3 kinase (PI3K)-
independent mechanism (Bolan et al., 2007).  
 Type 1 metabotropic glutamate receptors (mGluRI) have been reported to 
regulate DAT expressed by dendrites of substantia nigra DA neurons 
(Falkenburger et al., 2001). These investigators demonstrated that stimulation of 
subthalamic nucleus afferents resulted in DAT-mediated DA efflux. 
Pharmacological inhibition of DAT, as well as antagonism of mGluR1 receptors, 
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attenuated DA release from DA neurons. In another study, mGluR5 was reported 
to regulate DAT in vitro. Activation of mGluR5 by its selective agonist (S)-3,5-
dihydrophenylglycine (DHPG) decreased DA transport by DAT in striatal 
synaptosomes (Page et al., 2001). In these studies, mGluR5-dependent inhibition 
of DAT activity was dependent on signaling by CaMKII and PKC pathways.  
 Nicotinic acetylcholine receptors (nAChRs) have been reported to regulate 
DAT function. In vivo voltammetry studies provide evidence that systemic 
nicotine administration increases DA clearance in striatum, medial prefrontal 
cortex (mPFC) (Middleton et al., 2004), and nucleus accumbens (Hart and Ksir, 
1996). The dose-response profile of nicotine in modulating DA clearance in 
striatum and mPFC is different, possibly owing to differential expression of 
nAChR subunits. AMPH-stimulated DA release from prefrontal cortex brain slices 
was reported to increased following 5 µM nicotine application (Drew et al., 2000). 
AMPH-mediated DAT downregulation following nicotine administration were 
found to be PKC-dependent but CaMKII-independent (Drew and Werling, 2001). 
Thus, activation of PKC via mGluRI and nAChR may drive opposite effects on 
DAT activity. One possible explanation for this could be that processes 
supporting DA uptake and DAT-mediated DA efflux may be governed by different 
mechanisms.  
 Regulation of DAT by σ2 receptors (formally classified as opioid receptors) 
has also been reported. Activation of σ2 receptor by (+)-pentazocine enhances 
AMPH-stimulated DAT-dependent DA release in striatal slices (Izenwasser et al., 
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1998), as well as in PC12 cells (Weatherspoon and Werling, 1999). σ2 receptors 
have been suggested to regulate intracellular Ca2+ levels through their action on 
endoplasmic reticulum Ca2+ stores (Vilner and Bowen, 2000). In rat striatal slices, 
activation of σ2 receptors has been reporter to act through Ca2+ and PKC-
dependent mechanisms to stimulate DAT activity (Derbez et al., 2002). 
Conversely, in PC12 cells, σ2 receptors activation was found to increase AMPH-
stimulated DA efflux, stimulation dependent on CaMKII activation (Weatherspoon 
and Werling, 1999). Choice of model system and experimental designs likely 
dictate these regulatory differences. These studies with σ2 receptors reinforce 
the complexity in DAT regulation and demonstrate a need for more in-depth 
investigation using more precise pharmacological and genetic tools. 
 A recent addition to the list of receptors reported to regulate DAT is the 
trace amine-associated receptor 1 (TAAR1). TAAR1 is a Gs-coupled GPCR that 
signals through increasing cAMP production (Wainscott et al., 2007). TAAR1 is 
activated by trace amines like beta-phenylethylamine, as well as classic biogenic 
amines, and amphetamine-related psychostimulants. TAAR1 is expressed by 
substantia nigra DA neurons in primates and rodents (Xie and Miller, 2007, Xie et 
al., 2007) and its activation by DA or methamphetamine (METH) appears to lead 
to a PKA- and PKC-mediated reduction in DAT-mediated DA uptake. TAAR1 
activation also induced an increase in DA efflux via a PKC-dependent 
mechanism (Xie and Miller, 2007). Further studies of DAT regulation by TAAR1 
may be of clinical relevance in the treatment of METH addiction. 
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DAT-interacting proteins 
Multiple DAT-interacting proteins (DIPs) have been identified using yeast 
two-hybrid (Y2H) screens with specific DAT sequences as bait, with confirmation 
of interactions pursued in cells or brain preparations by co-immunoprecipitation 
(Torres, 2006). DIPs are theorized to regulate DAT somatic export, synaptic 
localization, and surface trafficking, as well as DAT functional properties. None of 
these interactions has as yet been shown to influence DAT in vivo.  
 Torres and colleagues, using the DAT C-terminus as bait in a Y2H screen, 
described the first DIP, Protein Interacting with C kinase-1 (PICK1) (Torres et al., 
2001). PICK1 is a PDZ (postsynaptic density 95/Discs large/zona occludens 1) 
domain containing protein that has been argued to be important for synaptic 
localization of DAT. The PDZ domain of PICK1 binds to a large number of 
membrane proteins especially proteins containing C-terminus PDZ type II binding 
motif.   PICK1 also has a BAR (Bin/amphiphysin/Rvs) domain. The BAR domain 
of PICK1 binds to lipids, mainly phosphoinositides (Xu and Xia, 2006). PICK1 
was originally identified as a PKC binding protein (Staudinger et al., 1995) and 
therefore, the PICK1-DAT interaction may be important in PKC-mediated 
regulation and trafficking of DAT. The Torres studies, the interactions between 
PICK1 and DAT were found to be mediated by the PDZ domain of PICK1 and the 
class II PDZ binding motif (LKV) that ends the C-terminus of DAT. PICK1/DAT 
interactions were reported to increase the number of surface DAT molecules, 
leading to an increase in DA uptake (Torres et al., 2001). However, more recent 
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studies from Getherʼs lab argue that surface targeting of transporter does not 
depend on PICK1 binding to the transporterʼs PDZ binding motif, but rather 
derives from residues (RHW) upstream of these sequences (Bjerggaard et al., 
2004). Moreover, these authors suggest that the ability of PICK1 to modulate 
DAT surface expression may derive from an effect on the export of DAT from 
ER/Golgi biosynthetic stores. Recent studies by Madsen and colleagues show 
that deletion of PDZ domain from PICK1 results in clustering of PICK1 and BAR 
domain-dependent redistribution of PICK1 to endosomal compartments (Madsen 
et al., 2008). These authors further show that under basal conditions, the PDZ 
domain and the linker region connecting PDZ domain and BAR domain fold over 
leading to inhibit interactions of the BAR domain with its targets. Disinhibition of 
the BAR domain leads to membrane interactions, membrane curvature, and 
altered protein trafficking (Madsen et al., 2008). These findings raise the 
possibility that the action of PICK1 with respect to DAT may be constrained by 
BAR domain interactions with the PICK1 PDZ domain, and thus be one target of 
the regulatory cascades impacting DAT trafficking out of the ER/Golgi or to and 
from the cell surface. 
 In the Y2H screen where PICK1 was identified, Caronʼs group identified a 
second DIP, the multiple Lin-11, Isl-1, and Mec-3 (LIM) domain-containing 
adaptor protein, Hic-5 (Carneiro et al., 2002). Hic-5 is a member of a focal 
adhesion-associated adaptor protein family and is closely related to paxillin. In 
addition to its membrane localization, Hic-5 has also been found localized to 
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nuclear compartments (Shibanuma et al., 2004), with suggestion that the protein 
may cycle between these compartments, though a functional significance of this 
idea has not been determined with respect to DAT. Hic-5/DAT interactions arise 
through Hic-5 LIM domains and membrane-proximal sequences of the DAT C-
terminus. Carneiro and colleagues reported that expression of DAT and Hic-5 in 
HEK 293 cells results in reduced DA uptake activity that arose from decreased 
DAT surface expression (Carneiro et al., 2002). Even though the physiological 
importance of DAT/Hic-5 interaction in vivo is unknown, Hic-5 is targeted by 
numerous signaling molecules (Shibanuma et al., 2012), and thus DAT 
interactions could connect the transporter to multiple intracellular signaling 
pathways. Recently, Carneiro and Blakely extended the generality of interactions 
of Hic-5 to other SLC6 family transporters, as well as their dynamic nature and 
occurrence in native preparations, with demonstration of PKC-dependent, 
SERT/Hic-5 interactions in human and mouse platelets (Carneiro and Blakely, 
2006).  Co-immunoprecipitation (co-IP) and 5-HT transport studies revealed that 
Hic-5 produces SERT inactivation and targets SERT to a membrane 
compartment that is permissive for PKC-dependent relocation of transporters 
from the cell surface. Interestingly, SERT/Hic-5 associations were reduced by 
PKC activation over the same time course as SERT internalization. Since 
association of intracellular SERT with Hic-5 was not detected, these authors 
concluded that Hic-5 participates in chaperoning SERT to membrane domains 
competent for PKC-dependent endocytosis (Carneiro and Blakely, 2006, Steiner 
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et al., 2008) and then dissociates thereafter or shortly following SERT 
endocytosis.  Studies examining DAT/Hic-5 interactions in DA terminals are 
needed to determine whether the SERT/Hic-5 model extends to DAT. 
  The synaptic vesicle associated protein α-synuclein is yet another protein 
found to interact with DAT, once again mediated by sequences in the 
transporterʼs C-terminus (Lee et al., 2001). Mutations in α-synuclein have been 
implicated in familial forms of Parkinsonʼs disease (Higuchi et al., 1998, Kruger et 
al., 1998), a disorder characterized by the degeneration of DA neurons. The 
physiological role of α-synuclein in vivo remains an active area of investigation 
(Chandra et al., 2005, Jin et al., 2011). DAT/α-synuclein interactions were first 
identified via a Y2H screen, and thereafter confirmed in neurons and co-
transfected cells (Lee et al., 2001, Lee et al., 2007). DAT/α-synuclein interactions 
have been found to cluster the transporter at the plasma membrane, to increase 
uptake activity and to enhance DA-induced cellular apoptosis (Lee et al., 2001), 
possibly via enhanced oxidative stress produced by oxidation of the 
neurotransmitter. The functional outcome of this interaction is somewhat 
controversial as one group has reported that DAT/α-synuclein interactions 
following heterologous expression of these molecules leads to decreased DAT 
activity (Wersinger and Sidhu, 2003). The same group also reported that 
disruption of microtubule networks results in increased DAT activity as a 
consequence of DAT-α-synuclein interactions (Wersinger and Sidhu, 2005). As 
these studies have largely been conducted via heterologous expression, the 
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importance of DAT/α-synuclein interactions for presynaptic DA homeostasis and 
signaling remains unclear. Indeed, α-synuclein knockout mice do not show 
significant changes in DAT activity or protein expression (Abeliovich et al., 2000), 
though regulatory control of DAT has yet to be examined in this model. 
 In another Y2H screen using the DAT C-terminus as bait, Fog and 
colleagues identified CaMKIIα as a DIP (Fog et al., 2006). DAT/CaMKIIα 
interactions were confirmed using GST pulldown experiments and co-IP studies 
of both transfected cells and brain lysates, as well as through 
immunocytochemical colocalization studies. These researchers demonstrated 
that CaMKIIα binds to the DAT C-terminus and leads to phosphorylation of the 
transporter, likely through sites in the N-terminus of DAT. Additionally, CaMKII 
binding and DAT phosphorylation were shown to be necessary for AMPH-
mediated DA efflux through DAT (Fog et al., 2006), providing evidence that 
conformational changes in the transporter that mediate DA efflux do not simply 
arise from substrate-mediated conformational changes, but involve a stabilized 
transition of DAT to an “efflux-willing” state. Whether DAT/CaMKIIα associations 
are constitutive, regulated or sensitive to disease-associated DAT mutations is 
unknown. 
 Recently, Melikianʼs group used a Y2H screen with a bait that encoded 
DAT C-terminal sequences 587-596 to identify a Ras-like GTPase, Rin, as a DIP. 
This interaction was confirmed through GST pull-downs, co-IP studies, and co-
localization studies using heterologous expression system. DAT/Rin interactions 
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are suggested to be essential for PKC-induced DAT downregulation and 
internalization (Navaroli et al., 2011). The actual mechanism by which DAT-Rin 
interaction leads to PKC-mediated DAT downregulation is still under 
investigation. Rin binds to, and activates calmodulin (Lee et al., 1996). Since 
CaMKIIα also interacts with the DAT C-terminus, it is possible that Rin may serve 
to activate DAT-bound CaMKII via its activation of calmodulin. Rin is also 
required for nerve growth factor (NGF)-stimulated neurite extension (Spencer et 
al., 2002) and p38 mitogen-activated protein kinase (MAPK) activation in 
response to NGF signaling (Shi et al., 2005). Since DAT trafficking has also been 
linked to MAPK signaling (Moron et al., 2003, Bolan et al., 2007), studies are 
needed to determine if Rin participates in this process. 
In summary, the DAT C-terminus is a site of interaction for multiple 
cytosolic proteins that have been argued to regulate DAT activity and expression. 
Understanding whether all of these associations occur together, are constitutive, 
or arise at different phases in the life cycle of the transporter needs further study. 
Since artificial systems provide the bulk of the data supporting the physiological 
significance of these findings, additional studies with DA neurons in vitro and in 
vivo are needed. 
Using the N-terminus of DAT as Y2H bait, two additional DIPs have been 
identified; Receptor for Activated C Kinase (RACK1), and syntaxin 1A. RACK1 
was originally identified as protein that binds activated PKC and recruits it to the 
plasma membrane, in proximity of its substrates (Ron et al., 1994). Co-
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immunoprecipitation from rat brain extracts has shown the presence of a ternary 
complex involving DAT-RACK1-syntaxin 1A (Lee et al., 2004).  It is tempting to 
speculate that this interaction between DAT and RACK1 may modulate function 
of the transporter via recruiting PKC to the membrane. Syntaxin 1A is a major 
component of the SNARE-mediated mechanism of synaptic vesicle fusion and 
neurotransmitter release (Sudhof and Rothman, 2009). GABA transporters 
(GAT1) (Beckman et al., 1998), glycine transporters (GLYT1) (Geerlings et al., 
2000), NET (Sung et al., 2003b) and SERT (Quick, 2002), have also been shown 
to interact with syntaxin 1A. Cervinski and colleagues have shown that syntaxin 
1A/DAT complexes are present in rat striatal synaptosomes, that syntaxin 1A 
cleavage enhances DAT activity, supporting a role for these complexes in DA 
neurons, though other mechanisms downstream of syntaxin 1A cleavage are 
possible (Cervinski et al., 2010).  
Syntaxin 1A transfection into NET expressing cells leads to increased 
transporter surface expression, likely due to the SNARE-mediated fusion role of 
syntaxin 1A. In contrast, this expression also leads to a decrease in NE uptake 
capacity, accompanied by a reduction in NE-activated NET currents (Sung et al., 
2003a). These authors showed that activation of PKC leads to a dissociation of 
NET and syntaxin 1A paralleled by NET internalization. Cervinski and colleagues 
have found that in rat striatal synaptosomes, cleavage of syntaxin 1A does not 
preclude PKC-dependent downregulation of DAT (Cervinski et al., 2010). 
Together, these findings suggest that NET and DAT interactions with syntaxin 1A 
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are likely to be part of a dynamic cycle by which transporters are brought to the 
presynaptic membrane, possibly to specialized microdomains (see below), and 
then regulated to provide for neural-activity dependent chances in transport 
function. 
The ability of syntaxin 1A to modulate currents has also been reported 
with SERT, where syntaxin 1A can dictate whether the transporter exhibits an 
electroneutral or electrogenic 5-HT transport cycle (Quick, 2003). Recent studies 
have shown that DAT/syntaxin 1A associations promote AMPH-induced DA 
efflux (Binda et al., 2008) and can regulate DAT channel activity (Carvelli et al., 
2008). In the C. elegans model, DAT/syntaxin 1A interactions have been reported 
to impact DA neurotransmission and behavior (Carvelli et al., 2008), to date the 
only evidence that these complexes are important in vivo  As to the dynamic 
nature of transporter/syntaxin 1A interactions, Quick demonstrated that PKC 
activation with phorbol esters destabilized GAT1/syntaxin 1A interactions, 
possibly through phosphorylation of the syntaxin 1A-associated protein munc-18 
(Beckman et al., 1998). Recent studies by the Galli lab suggest that 
phosphorylation of syntaxin 1A by casein kinase 2 (CK2) destabilize 
DAT/syntaxin 1A interactions, leading to enhanced AMPH-mediated DA efflux 
(Cartier 2011). How these findings reflect changes in second messenger-based 
signaling pathways, such as those mediated by PKC and CaMKII requires further 
analysis.  
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With regard to coordinating DA release and reuptake, Lee and colleagues 
have reported that a direct interaction between DAT and D2S receptors, 
mediated by the DAT N-terminus, can modulate the DAT function (Lee et al., 
2007). This protein-protein interaction has great significance as both proteins are 
present at DA terminals and the associations may be part of a mechanism to 
synchronize DA release and clearance.  
DAT-membrane microdomain associations 
The term “Lipid raft” refers to the dynamic clustering of sphingolipids and 
cholesterol to form membrane microdomains that within the lipid bilayer.  Rafts 
are proposed to function as platforms for the attachment of proteins when 
membranes are moved around inside the cell and during signal transduction 
(Simons and Ikonen, 1997, Lingwood et al., 2009). For a long time, membrane 
microdomain associations have been speculated to impact DAT expression, 
function, trafficking, and lateral mobility on the cell surface. Recently, Adkins and 
colleagues demonstrated the localization of DAT in specialized membrane 
microdomains, limits the lateral mobility of DAT and regulates DA transport 
capacity (Adkins et al., 2007). Since then a number of groups have confirmed this 
finding (Foster et al., 2008, Hong and Amara, 2010, Cremona et al., 2011). 
Foster and colleagues have suggested that PKC activation by β-PMA leads to 
DAT internalization through a non-raft fraction and that raft-associated DAT might 
undergo cholesterol-dependent, trafficking-independent regulation (Foster et al., 
2008).  
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With respect to DAT trafficking, the redistribution of DAT from the plasma 
membrane to intracellular compartments in response to PKC activation has been 
reported to be a clathrin-dependent and dynamin-dependent endocytic 
mechanism (Daniels and Amara, 1999, Sorkina et al., 2005, Foster et al., 2008). 
AMPH-induced DAT trafficking has also been reported to be clathrin-dependent. 
These studies suggest that membrane domains supporting PKC and 
psychostimulant-induced endocytosis may originate from a common, or similar, 
membrane compartment, discussed further below.	  
 Hong and Amara recently demonstrated the effects of cholesterol 
depletion on DAT conformation (Hong and Amara, 2010). After a mild-detergent 
extraction, DAT was found in cholesterol-rich lipid rafts. Increasing membrane 
cholesterol content using water-soluble cholesterol, these investigators observed 
an increase in DAT binding to cocaine analogs without a parallel increase in DAT 
surface expression. Using accessibility of DAT cysteine residues to a membrane-
impermeable maleimide-biotin conjugate, DAT was found to favor an outward-
facing conformation in lipid rafts, which may indicate a modulatory role of 
surrounding lipid content on DAT ligand interactions (Hong and Amara, 2010). 
The authors suggest that harsher treatments to remove cholesterol in earlier 
studies may have led to changes in DAT activity through non-specific 
mechanisms. The methods described in this study should be very useful in future 
studies that probe the functional significance and dynamic status of DAT in 
membrane microdomains. 
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 Consistent with the findings of Hong and Amara, Cremona and colleagues 
demonstrated an association of DAT with the lipid-raft associated protein flotillin-
1, (Cremona et al., 2011). DAT/flotillin-1 interactions were shown to be required 
for both the localization of DAT to lipid rafts and AMPH-induced DA efflux, as well 
as for PKC-mediated DAT internalization. Treatment of cells with phorbol esters 
was found to lead to phosphorylation of flotillin-1 at Ser 315, a modification that 
was found to be essential for DAT endocytosis. These studies may explain the 
finding that PKC activation leads to DAT internalization in a DAT 
phosphorylation-independent manner (Granas et al., 2003). Although DAT is 
phosphorylated in cells and synaptosomes by activators of PKC (Huff et al., 
1997, Vaughan et al., 1997), this phosphorylation may play a role in DAT function 
versus DAT trafficking, with phosphorylation on raft-associated proteins of 
greater significance in endocytosis. Since AMPH-induced DA efflux, as noted 
above, is dependent on DAT N-terminal phosphorylation and CaMKII 
activation(Khoshbouei et al., 2004, Fog et al., 2006), a critical role for flottilin-1 
reinforces the idea that DAT membrane compartmentation, trafficking, and 
catalytic function are coordinated via membrane microdomains. Cremona and 
colleagues also provide evidence that flotillin-1 participates in PKC-mediated 
DAT endocytosis. Both SERT and DAT demonstrate endocytic and functional 
regulation, though the signaling pathways supporting their regulation appear 
somewhat distinct (Steiner et al., 2008), and SERT-mediated 5-HT efflux has not 
received the same degree of attention as DAT-mediated DA efflux.  
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DAT regulation by intracellular signaling pathways 
In addition to (but likely in concordance with) regulation of DAT by DIPs, 
DAT is believed to be regulated through covalent modifications, including 
phosphorylation, ubiquitination and lipid modification. The importance of these 
modifications for DAT trafficking, function and turnover are, to date, based on in 
vitro studies, most conducted following heterologous expression though several 
studies have been conducted ex vivo with brain synaptosomes (Vaughan et al., 
1997). The development of transporter knock-in mouse models (Herrstedt 
Hansen, 2011, Mergy, 2011), as well as studies of DAT in powerful invertebrate 
models, including C. elegans (Jayanthi et al., 1998, Nass et al., 2001, Carvelli et 
al., 2004, McDonald et al., 2006) and Drosophila melanogaster (Porzgen et al., 
2001), portend an increased opportunity to tackle questions related to in vivo 
relevance of DAT post-translational modifications in the coming years. 
 Canonical Ser/Thr phosphorylation sites, and many potential noncanonical 
Ser/Thr sites, are found on the DAT N- and C-termini, as well as on intracellular 
loops. Numerous studies demonstrate that DAT activity is associated with 
activation or inhibition of Ser/Thr protein kinases, including PKC, PKA, MAPKs, 
such as ERK1 and 2, CaMKII, and PI3K (Zapata and Shippenberg, 2002, Bolan 
et al., 2007, Blakely and Edwards, 2012). No studies to date have reported 
evidence of basal or regulated DAT phosphorylation following activation of 
tyrosine kinases. Although evidence supporting insulin receptor modulation of DA 
clearance and DAT trafficking has been advanced (Carvelli et al., 2002, Daws et 
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al., 2011), it is unclear whether this modulation is constitutive or dynamic since 
the paradigms examined so far either exploit treatments with PI-3K inhibitors or 
monitor DAT following insulin deprivation, followed by rescue of normal DAT 
trafficking/function with insulin restoration (see below). 
 Activation of PKC, either by exogenous application of phorbol esters such 
as β-PMA (Huff et al., 1997, Vaughan et al., 1997, Zhang et al., 1997, Zhu et al., 
1997, Daniels and Amara, 1999, Loder and Melikian, 2003, Foster et al., 2008), 
or indirect stimulation through the G protein-coupled substance P receptor 
(Granas et al., 2003), has been reported to produce significant DAT 
downregulation along with decreased cell surface expression. PKC-dependent 
downregulation of DAT activity is thought to be primarily due to the intracellular 
accumulation of the transporter (Zhang et al., 1997, Zhu et al., 1997, Melikian 
and Buckley, 1999, Granas et al., 2003, Loder and Melikian, 2003), and was 
initially believed to involve PKC-dependent DAT phosphorylation. Although PKC 
activation using β-PMA treatment on striatal synaptosomes does increase DAT 
phosphorylation (Huff et al., 1997, Vaughan et al., 1997, Foster et al., 2002), 
more recent evidence suggests that DAT phosphorylation is not necessary for 
DAT downregulation (Foster et al., 2002, Granas et al., 2003). Possibly, N-
terminal phosphorylation part of a redundant mechanism that insures appropriate 
control of transporter trafficking. We must also admit that our tools are likely quite 
limited with respect to following more subtle properties of “DAT activity”, as well 
as in detecting nuances in DAT trafficking pathways that may be altered by loss 
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of phosphorylation sites. We also have to recognize that no studies investigating 
a role of DAT phosphorylation involve an in vivo manipulation of DAT 
phosphorylation sites. Thus, current models, even ones reported in the present 
thesis, should be cautiously interpreted and will need extending through more 
physiologically relevant preparations.   
 The lack of a requirement for DAT phosphorylation in PKC-mediated DAT 
downregulation led to a search for other post-translational modifications that 
might be critical for regulated DAT trafficking. In this regard, PKC activation has 
been found to increase DAT N-terminal ubiquitination. In MDCK cells, DAT 
ubiqutination has been associated with lysosomal degradation (Daniels and 
Amara, 1999), though in other cells, the modification has been associated with 
endocytosis of the transporter, without a discernible reduction in protein levels 
(Miranda et al., 2005, Miranda et al., 2007).  
Despite a lack of a direct role in DAT trafficking, PKC-induced 
phosphorylation of DAT may be critical for other aspects of DAT function, such as 
DA efflux (Kantor and Gnegy, 1998, Johnson et al., 2005b). Indeed, Cowell and 
colleagues showed in striatal slices that DAT phosphorylation following PKC 
activation is paralleled by DAT-dependent DA efflux (Cowell et al., 2000). These 
data are consistent with both trafficking-dependent and independent roles for 
PKC in regulating DAT function. Ramamoorthyʼs (Jayanthi et al., 2004) and 
Blakelyʼs groups (Zhu et al., 2005, Steiner et al., 2008) have provided evidence 
that NET and SERT undergoes both trafficking-dependent and trafficking-
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independent modes of regulation, suggesting that the control of DAT described 
here may be further evidence of a more general phenomenon.  
 The finding by Carvelli and co-workers that a 5 hour treatment of serum-
starved, DAT-transfected HEK-293 cells with 1 µM insulin stimulates DAT 
activity, lead to an association of PI-3 kinase-linked pathways to DAT regulation 
(Carvelli et al., 2002). Garcia and colleagues demonstrated that a dominant 
negative form of Akt, an effector downstream of PI-3K, was able to block the 
effects of insulin of DAT expressed by these cells (Garcia et al., 2005). 
Consistent with these findings, studies by Galliʼs lab have demonstrated that 
treatment of rat brain synaptosomes with a PI-3K inhibitor reduces DAT function 
(Carvelli et al., 2002). The findings that insulin application to cells expressing 
DAT displayed increased DA uptake (Carvelli et al., 2002), and that rats made 
hypoinsulinemic by fasting exhibited decreased rate of DA uptake (Patterson et 
al., 1998) is consistent with a supportive role of insulin signaling and PI-3K linked 
pathways in sustaining DAT function.  
 Interestingly, AMPH self-administration is reduced in rats that are made 
hypoinsulinemic by injection of streptozotocin (Owens et al., 2005). Collectively, 
In vitro studies suggest that hypoinsulinemia may regulate the actions of AMPH 
by inhibiting the insulin downstream effectors PI3K and Akt, which we have 
previously shown are able to fine-tune DAT cell-surface expression (Carvelli et 
al., 2002, Garcia et al., 2005, Wei et al., 2007b) Finally, in vivo, using functional 
magnetic resonance imaging (fMRI) the ability of AMPH to elicit positive blood 
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oxygen level-dependent signal changes in the striatum was dependent on intact 
insulin signaling (Williams et al., 2007) Recently, Galliʼs group has extended their 
investigations of a role of PI3K/Akt pathways in DAT regulation to implicate a 
downstream target of Akt, mTOR, in NET trafficking and NE transport (Robertson 
et al., 2010, Siuta et al., 2010). These latter findings, derived from studies of 
conditional mTOR-knockout mice, included behavioral changes, such as 
disrupted pre-pulse inhibition (PPI), that are found in schizophrenic subjects. PPI 
deficits could reversed by the NET antagonist desipramine (Siuta et al., 2010), a 
surprising finding given that the brains of mTOR knockout mice exhibit gross 
changes linked to the role of mTOR in protein translation. Regardless, these 
studies warrant further consideration of PI3K-Akt-mTOR-DAT/NET pathways in 
modulation of catecholamine transporter capacity as well as in neuropsychiatric 
disorders.  
 Multiple MAPKs have been implicated in DAT regulation. Initially, inhibitors 
of p42 and p44 MAPK were found to induce a reduction in DAT activity and to 
increase internalization in transfected cells and striatal synaptosomes (Lin et al., 
2003, Moron et al., 2003). Unlike PI-3K and MAPK, inhibition of PKA has been 
shown to increase DAT activity and surface expression in heterologous 
expression systems (Pristupa et al., 1998). However, striatal synaptosomes 
display opposite effects upon PKA activation (Page et al., 2004) leaving the role 
of PKA signaling in DAT regulation unclear 
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 Together, the studies describe above paint a complex and incomplete 
picture regarding control of DAT activity and DA clearance. Regulation of DAT 
likely involves multiple intracellular signaling pathways, acting across different 
time domains, through multiple DIPs. A further characterization of DAT regulatory 
events could inform our understanding and treatment of DA-linked 
neuropsychiatric disorders, including schizophrenia, ADHD and addiction.  
 
Impact of Psychostimulants on DAT 
Given the dynamic role of DAT in controlling DA signaling, it is no surprise 
that drugs targeting DAT have profound biochemical and physiological effects. 
These effects can be beneficial, such as the use of methylphenidate (Ritalin®) 
and mixed amphetamine formulations (e.g. Adderall®) for the treatment of 
ADHD. Other drugs, however, are highly addictive and can lead to devastating 
consequences for the individual, his or her family, and their community.  
 Cocaine is a conventional, and rapidly acting, competitive DAT antagonist 
whereas the actions of AMPH are more complex, as noted above. In addition to 
their rapid effects in blocking DA uptake and/or producing DAT-mediated DA 
efflux, these agents also influence the subcellular localization of DAT proteins 
(Saunders et al., 2000, Daws et al., 2002, Gnegy et al., 2004). Although effects of 
cocaine on DAT cell surface expression have been reported, the findings are 
somewhat inconsistent. Daws and colleagues reported that 10 min application of 
10 µM cocaine increases DA uptake and DAT cell surface expression in DAT 
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transfected HEK 293 cells (Daws et al., 2002). In contrast, Vaughanʼs group have 
suggested that cocaine produces no effects on DAT expression and regulation in 
heterologous cell expression in system (Gorentla and Vaughan, 2005). Chronic 
cocaine use has been reported to increase DAT binding in brains of abusers 
(Little et al., 1993, Mash et al., 2002), though others have reported that striatal 
DAT protein levels are decreased in cocaine abusers (Wilson et al., 1996). 
Possibly, these observations relate to the changes in conformation for ligand 
recognition that were seen with membrane cholesterol depletion (Hong and 
Amara, 2010). Alterations in DA neurotransmission and presence of excess DA 
could also lead to downregulation of DAT as a compensatory mechanism due to 
psychostimulant addiction. Further investigation of these phenomena is 
warranted; as such changes may underlie the psychiatric component associated 
with addiction and relapse. 
 With prolonged treatments, amphetamines (AMPH and METH) produce a 
reduction in DA transport, accompanied by a loss in cell surface expression 
(Saunders et al., 2000, Gulley et al., 2002). METH, a highly addictive 
psychostimulant, produces a significant reduction in brain DA content and a loss 
of DAT protein and/or DA axon degeneration with chronic use (McCann et al., 
1998, Sekine et al., 2001).  The endocytic effects of AMPH are dependent on 
AMPH transport and PKC activity, as they can be blocked by cocaine and PKC 
inhibitors (Kantor and Gnegy, 1998, Saunders et al., 2000).  
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 AMPH-induced DA efflux is regulated by both PKC (Kantor and Gnegy, 
1998) and CaMKII (Fog et al., 2006). Consistent with these observations, AMPH, 
likely through its weak base properties, induces a rise in intracellular Ca2+ (Gnegy 
et al., 2004). Activation of either kinase leads to DAT phosphorylation, with 
evidence consistent in both cases with modification of N-terminal serine residues 
as 1) elimination of these sites leads to a loss of phorbol ester-activated DAT 
phosphorylation (Foster et al., 2002, Granas et al., 2003) and 2) alanine 
substitution at N-terminal serines abolishes AMPH-induced efflux (Khoshbouei et 
al., 2004). As noted above, CaMKII interacts directly with distal sequences of the 
DAT C-terminus (Fog et al., 2006). No such interaction has been suggested for 
PKC, although PKCβ has been shown to both regulate DAT and colocalize with 
the transporter in mesencephalic neurons (Chen et al., 2009, O'Malley et al., 
2010a). Together, these studies suggest a role of DAT phosphorylation in 
modulating DAT reversal and DA efflux. Along with findings of a PKC-modulated 
interaction of DAT with the lipid raft-associated protein flotillin-1 (Cremona et al., 
2011), these studies suggest a model whereby AMPH acts initially to prevent DA 
clearance, and then after AMPH transport, the psychostimulant elevates cytosolic 
DA and Ca2+, with a subsequent activation of PKC and CaMKII. Kinase activation 
leads to phosphorylation of DAT on the transporterʼs N-terminus to stabilize 
transporters, located in lipid rafts, in an efflux-competent state. The latter effect is 
likely produced by alterations in the association of the DAT N-terminus with DIPs, 
including syntaxin 1A and flotillin-1, but likely several other proteins 
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Dopamine Transporter and Human Disorders 
Disruption of DA neurotransmission has been linked to multiple 
neurodegenerative and psychiatric disorders. Here, I focus on two of these 
disorders, juvenile dystonia, and ADHD, as they relate to genetic alterations in 
DAT that form the basis of this thesis. 
 ADHD is the most commonly diagnosed disorder of childhood, affecting 3-
5% of US school-age children (AmericanPsychologicalAssociation, 1994). The 
disorder is characterized by deficits in attention/cognitive function and evidence 
of hyperactivity/impulsivity. ADHD is highly heritable, with males four times more 
likely to be affected than females (AmericanPsychologicalAssociation, 1994).  
ADHD has been found to exhibit significant comorbidity with bipolar disorder 
(BPD). The American Psychiatric Association has developed criteria to clinically 
diagnose the disorder that involves behavioral assessment of the child as well as 
parent and teacher observations. There are no known biological markers that can 
serve to help diagnose ADHD, which makes it difficult to distinguish the disorder 
from other mental disorders with cognitive deficits. 
 Brain imaging and genetic studies are consistent with a contribution of 
altered brain DA signaling to ADHD risk. Using iodine-123 labeled N-(3-
iodopropen-2-yl)-2beta-carbomethoxy-3beta-(4-chlorophenyl) tropane ([123I]IPT) 
single-photon emission tomography (SPECT), DAT binding in the basal ganglia 
has been found to be increased in Asian children with ADHD compared to normal 
children (Cheon et al., 2005).  Multiple studies have also found an association 
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between DAT binding and adults with ADHD (Dresel et al., 2000, Krause et al., 
2000) with one exception (van Dyck et al., 2002). ADHD traits have significant 
heritability and multiple genetic studies demonstrate association between ADHD 
and DAT polymorphisms or haplotypes, with greatest focus being a variable 
number tandem repeat (VNTR) in the 3'-untranslated region of the human DAT 
(DAT) gene, a variant whose functional relevance remains debated (Cook et al., 
1995). Association studies have also implicated the DA D4 receptor in ADHD 
(Holmes et al., 2002, Kirley et al., 2004). In addition to these genes, significant 
association has been found with genes that encode DA D5 receptors, DA beta-
hydroxylase, SERT, 5-HT1B receptors, and synaptosomal associated protein-25 
(SNAP-25) (Brookes et al., 2006). Although multiple genes appear to contribute 
to the heritability of, and risk for, ADHD, it seems reasonable to speculate that 
groups of these genes ultimately will be linkable into coherent molecular 
networks that control the development, function and plasticity of brain synapses, 
in general, and of DA synapses in particular.  
 DAT knock-out (KO) and knockdown mice display hyperactivity (Giros et 
al., 1996, Zhuang et al., 2001) as well as cognitive alterations (Giros et al., 1996, 
Pogorelov et al., 2005). These findings suggested that loss of DAT expression or 
function could contribute to ADHD, with the mice described above as models that 
might be of valuable to further dissect the disorder in ways impossible with 
human subjects. However, there is no evidence for DAT loss of function 
mutations in ADHD subjects, raising concern as to the legitimacy of these mouse 
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models for the study of ADHD. Reinforcing these concerns, Kurian and 
colleagues recently identified subjects with infantile Parkinsonism-dystonia (IPD) 
that possess homozygous, loss-of-function DAT mutations (Kurian et al., 2009). 
Although these findings do not support a role for severe reductions in DAT 
expression in ADHD, they do encourage further investigation of DAT alterations 
as a risk for movement disorders, particularly in syndromes associated with 
dystonia. An important, though not obligate reason for considering DAT with 
respect to ADHD risk factors is the fact that multiple medications used to 
successfully treat ADHD also target DAT. As noted earlier, methylphenidate 
(Ritalin®) blocks DAT whereas AMPHs (typified by the mixed AMPH, Adderall®) 
acts as a DAT substrate and induces DA efflux. The efficacy of DAT-directed 
agents in the treatment of ADHD, along with their rapid action, is consistent with 
compromised DA signaling in the disorder. However, these findings are just as 
consistent with the utility of these agents in enhancing signaling at perfectly 
normal DA synapses that can overcome deficits originating elsewhere. 
 Detailed characterization of previously identified, but not clinically 
associated DAT coding variants failed to demonstrate specific deficits in either 
DAT function or regulation (Mazei-Robison and Blakely, 2005), except for the 
V382A variant, which displayed an intriguing regulatory deficit. PMA treatment (1 
µM, 30 minutes) of V382A transfected cells was found to reduce DAT activity 
without accompanying endocytosis, revealing a capacity of transporters to 
display catalytic inactivation, as well as transporter endocytosis, as a mechanism 
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of DAT downregulation (Mazei-Robison and Blakely, 2005). Although these 
findings hint that natural variation in DAT may provide insights into components 
of DAT regulation more difficult to observe in the WT transporter, the lack of a 
clinical correlation with the V382A variant prevents further extrapolation to this 
variantʼs potential physiological significance. 
 Owing to a lack of evidence of functionally perturbed, DAT coding variants 
associated with DA-linked disorders, the Blakely lab pursued a search for 
functional polymorphisms in subjects with ADHD (Mazei-Robison et al., 2005, 
Mazei-Robison et al., 2008). These studies resulted in the identification of the 
A559V coding variant, carried by two brothers diagnosed with hyperactive 
predominant ADHD or combined-type ADHD. Both brothers were also 10/10 for 
the DAT 3ʼ VNTR, and thus homozygous for the VNTR allele most often 
associated with ADHD, suggesting the possibility of a “double-hit” model.  
Although the kindred containing these subjects is small, Mazei-Robison and 
coworkers were able to demonstrate transmission across two generations, 
passed from grandmother to mother to the two boys.  
 The DAT A559V variant was the first coding variant to be identified in 
independent studies, having been separately identified in a female subject with 
BPD (Grunhage et al., 2000, Mazei-Robison et al., 2005). Despite the screening 
of many hundreds of affected and unaffected subjects since, the A559V variant 
has not been uncovered, indicating that it is indeed a rare variant as opposed to 
a common polymorphism. Interestingly, BPD and ADHD are comorbid (Faraone 
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and Tsuang, 2003) and the manic phases of BPD often display hyperactivity and 
impulsivity. Children of BPD subjects are three times more likely to have ADHD, 
and children of ADHD patients are twice as likely to develop bipolar disorder in 
their adulthood (Faraone and Tsuang, 2003). In both cohorts in which DAT 
A559V was identified, subjects are heterozygous for the substitution, suggesting 
that the variant, if it contributes to disease risk, likely acts dominantly. 
 Mazei-Robison and colleagues evaluated the functional impact of the DAT 
A559V in transfected HEK-293 cells. Under basal conditions, A559V exhibits 
normal DAT activity, and surface expression (Mazei-Robison et al., 2005). 
Remarkably, DAT was found to display anomalous DA efflux (ADE) under basal 
conditions that could be blocked by both AMPH and methylphenidate (Mazei-
Robison et al., 2008). These investigators also observed that A559V ADE could 
be greatly enhanced by membrane depolarization, and DA efflux was supported 
by D2 receptor stimulation and increased DAT channel activity (Mazei-Robison et 
al., 2008, Bowton et al., 2010). The properties of the DAT A559V variant led 
these investigators to propose that idiopathic ADHD may feature disrupted DAT 
function or regulation, thereby disrupting the fidelity of DA signaling that can be 
restored through the use of psychostimulants. Possibly, ADHD-associated ADE 
may have parallels in other biogenic amine transporter-linked disorders, such as 
anxiety and depression (associated with altered SERT and/or 5-HT signaling) 
and cardiovascular disorders (associated with altered NET and/or NE signaling).    
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Specific Aims 
This dissertation specifically seeks to characterize functional alterations 
possessed by a novel, ADHD-associated coding variant DAT-R615C (DAT 615C) 
and determine whether there are shared or distinct properties with the previously 
identified DAT variant A559V, To achieve these goals, I have pursued the 
following aims: 
1) Determine impact of DAT 615C variant on basal total and surface 
expression as well as DAT activity including DA uptake and DA efflux. 
2) Monitor regulatory changes associated with DAT 615C and A559V after 
AMPH and β-PMA treatment (Surface and total expression, DA uptake) 
3) Examine protein-protein interactions that might alter due to DAT 615C 
variant 
4) Determine whether DAT 615C can act dominantly  
5) Monitor DAT phosphorylation levels for DAT 615C and A559V 
6) Verify the DAT 615C and A559V mutations do not alter membrane 
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CHAPTER II 	  
MATERIALS AND METHODS 	  
Materials 
DMEM and FBS were from Gibco. Mouse anti CaMKII antibody (MA1-
048), TCEP, Sulpho-NHS-SS-Biotin, and Streptavidin agarose resin were from 
Thermo Fisher. [3H]DA (30-50 Ci/mmol) and [32P]orthophosphoric acid (8500-
9120 Ci/mmol) were from PerkinElmer. Alexa Fluor 647 CTxB was from 
Invitrogen. KN-93, KN-92 and β-PMA were from EMD biosciences. Rat and rabbit 
anti-DAT antibodies were from Millipore (MAB369 and AB5803 respectively). 
Mouse anti-flotillin-1 antibody was from BD Biosciences (Catalog # 610820). 
Secondary antibodies were obtained from Jackson Laboratories. Other reagents 
were obtained from Sigma.  
 
ADHD subject collection and ascertainment 
Subject recruitment and ascertainment for U.S. ADHD probands has been 
previously described (Mazei-Robison et al., 2005, Mazei-Robison et al., 2008). 
Additional subjects from Ireland were also enrolled from child guidance clinics 
and ADHD support groups around Ireland. The age range of the probands was 
between 5 and 14 years, with males accounting for 88% of the cases. To 
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establish DSM-IV diagnoses, one or both parents were interviewed using the 
Child and Adolescent Psychiatric Assessment (CAPA). To fulfill DSM-IV ADHD 
criteria for symptom pervasiveness, information regarding ADHD symptoms at 
school was obtained from teachers using a semistructured teacher telephone 
interview. ADHD symptom dimensions, as well as comorbid disorders such as 
Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD) were obtained 
from the Child and Adolescent Psychiatric Assessment (CAPA). A positive family 
history of ADHD was defined by at least one parent scoring 36 or greater on the 
25 item subscale of the Wender Utah Rating Scale (WURS). A 25-item sub scale 
was used in with a cutoff score of 36 or greater being 96% sensitive and specific 
for a retrospective diagnosis of childhood ADHD in the parent. 
 
PCR amplification of DAT exons and polymorphisms screening via 
temperature gradient capillary electrophoresis (TGCE) 
PCR amplification, screening and sequence confirmation was performed 
as described previously (Mazei-Robison et al., 2005).  
 
Cell culture, transfections, and stable cell line generation 
Flp-In™ 293 cells were used to generate stable lines expressing either 
DAT 615R or DAT 615C following the manufacturerʼs protocol (Invitrogen™). 
Selection media contained 100 µg/ml Hygroycin B. HEK 293T cells used for 
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transient transfections were cultured, maintained and transfected as described 
previously (Mazei-Robison and Blakely, 2005). 
 
DA transport assays 
  [3H] DA transport assays were performed in triplicate or quadruplet in 24 
well plates as described previously (Apparsundaram et al., 1998). Briefly, cells 
were washed with Krebs-Ringers-HEPES (KRH) (130 mM NaCl, 1.3 mM KCl, 2.2 
mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 10 mM HEPES, pH 7.4) buffer and 
were incubated in the uptake assay buffer (KRH, 10 mM glucose, 100 µM 
pargyline, ascorbic acid, and 10 µM tropolone) before incubation with [3H] DA for 
10 min followed by three 40C washes. To determine non-specific uptake, parallel 
wells were incubated with 1 µM GBR 12909 5 min prior addition of [3H] DA. For 
single point uptake assays, 50 nM [3H] DA was used. For saturation kinetic 
analyses, six different DA concentrations were used (0.05, 0.1, 0.5, 1, 2, and 3 
µM or 0.05, 0.1, 0.5, 1, 3, and 6 µM). Serial dilution from a stock made with 5% 
[3H] DA was used for saturation analyses, except for the 50 nM concentration 
where 100% tritiated substrate was used. For all inhibitors, six concentrations 
(0.001, 0.01, 0.1, 0.5, 1, 10 µM) were tested to determine IC50 values. With 
AMPH treatments, cells were rapidly washed with ice-cold KRH buffer and 
warmed back up to 370C using uptake assay buffer for 5 min before addition of 
[3H] DA for a further 3 min incubation. The shorter uptake time was used to 
reduce confounds from DA efflux due to the presence of intracellular AMPH. 
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MicroScint scintillation cocktail was added to the wells at the end of the assay 
and DA uptake was measured using a TopCount Scintillation Counter. Mean +/- 
SEM values reported derive from 3-6 independent experiments. 
 
IDT 307 Uptake Assays 
 Flp-In HEK cells were plated onto PDL coated 96 well plates and cultured 
for 24-36 hrs. Cells were washed twice with warm KRH and incubated with KRH 
for 10 min with or without GBR 12909 before addition of IDT 307. For saturation 
kinetic analyses, five different IDT 307 concentrations were used (0.5, 1, 5, 10, 
and 20 µM). Plate was placed in the FlexStation and fluorescence was measured 
at 400 nM for 10 min. and endpoint fluorescence was used to generate the 
saturation curve. Data was analyzed using Soft-Max Pro, Microsoft Excel, and 
Prism softwares. 
 To determine AMPH-induced IDT 307 efflux, cells were preloaded with IDT 
307 for 10 min prior to washing the cells with KRH to remove excess extracellular 
IDT 307 and addition of AMPH. Change in fluorescence was measured for 15 
min. as described above. Data was normalized to 100% at a time point 100 sec. 
prior to AMPH addition. This was necessary to ensure IDT 307 fluorescence was 
stable before addition of AMPH.      
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Cell surface biotinylation, biotinylation internalization, and biotinylation 
recycling assays 
Cells were seeded in 6 well plates and incubated for 36-48hrs before 
experiments. Cells were washed twice with warm KRH buffer before drug 
treatments. At the end of the treatment time, cells were placed on ice and 
washed rapidly twice with ice-cold PBS (136 mM NaCl, 2.5 mM KCl, 1.5 mM 
KH2PO4, 6.5 mM Na2PO4, 2.8 mM glucose) containing 0.1mM CaCl2 and 1mM 
MgS04 Cells were incubated with sulphosuccinimidyl1-2-(biotinamido)ethyl-1,3-
dithioproprionate-biotin (Sulpho-NHS-SS-Biotin) for 30 min at 40C. Excess biotin 
was quenched by 2 washes with 0.1 M glycine in PBS and cells were solubilized 
using radioimmunopreciptation assay (RIPA) (100 mM Tris pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 0.1 % SDS, 1 % TritonX-100, 1 % sodium deoxycholate) 
buffer for 30 min at 40C.  
To determine the internalization rate, we used a modified version of a 
previously published protocol (Holton et al., 2005). Briefly, cells seeded on 2 
different plates were labeled with Sulpho-NHS-SS-Biotin for 30 min at 40C and 
quenched with 0.1 M glycine in PBS. One plate was mainlined at 40C to 
determine total surface expression and stripping efficiency. The other plate was 
warmed by 3 rapid washed with warm PBS and cells were incubated with warm 
PBS at 370C for 30 min either with or without AMPH to allow trafficking of the 
surface proteins. At the end of incubation, plates were transferred onto ice and 
cells and washed 3 times with ice-cold PBS followed by 3 washes with NT buffer 
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(150 mM NaCl, 1 mM EDTA, 0.2% BSA, 20 mM Tris pH 8.6). The biotin signal 
remaining on the surface from the 370C plates and stripping control wells from 
40C plates were stripped using 50 mM tris(2-carboxyethyl)phosphine (TCEP) in 
NT buffer for 60 min at 40C. Fresh stripping solution was added after the first 30 
min to ensure optimal stripping efficiency. Cells were washed rapid three times 
with ice-cold NT buffer followed by ice-cold PBS and solubilized using RIPA 
buffer for 30 min at 40C. Protein concentration was determined using the BCA 
protein assay and equal protein amounts were incubated with pre-washed 
streptavidin beads for 2hr or overnight at 40C. Streptavidin beads were washed 
three times with RIPA buffer and bound proteins were eluted using Laemmli 
sample buffer (LSB) and analyzed using SDS-PAGE, followed by western 
blotting. A rat anti-DAT antibody (Millipore-MAB 369, 1:5000) was used to 
visualize DAT and mouse anti β-actin (Sigma-a5316, 1:5000) antibody was used 
to detect β-actin as a loading control. HRP-conjugated goat anti rat and mouse 
secondary antibodies (1:10000) were used.  
Recycling rates were estimated using a biotinylation-recycling assay. Cells 
were labeled with Sulpho-NHS-SS-Biotin for 60 min at 370C to achieve labeling of 
both surface and recycling intracellular proteins. Cells were placed on ice and 
cooled by washing with ice-cold PBS, followed by NT buffer three times each. 
Surface biotin labeling was stripped using 50 mM TCEP in NT buffer for 90 min at 
40C. After an initial 60 min of stripping, fresh TCEP solution was added for the 
remaining 30 min to ensure efficient stripping, assessed via western blots. 
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Following stripping, cells were washed rapidly three times with ice-cold NT buffer 
followed by three times with ice-cold PBS buffer. One plate was maintained at 
40C, and the other plate was warmed by washing three times with 370C PBS. 
Cells were then incubated for 30 min either with or without AMPH at 370C. At the 
end of the incubation, cells were again placed on ice and washed three times 
with ice-cold PBS followed by NT buffer. Biotin signal from intracellular DAT that 
recycled to the surface was stripped by incubating cells in 50 mM TCEP in NT 
buffer on ice for 60 min, with fresh stripping buffer added after 30 min. Cells were 
then washed three times with ice-cold NT buffer followed by three washes with 
ice-cold PBS buffer and solubilized using RIPA buffer for 30 min at 40C. 
Streptavidin pulldown and western blots were performed as described above.  
 
Co-immunoprecipitation (co-IP) assays 
DAT-CaMKII co-IP 
HEK 293T cells were seeded on 10 cm dishes and co-transfected with 
pEYFP-HA-DAT-WT (615R) (gift from Dr. Alexander Sorkin) or the pEYFP-HA-
DAT 615C variant and CaMKIIα (gift from Dr. Roger Colbran) 24hrs later. The 
pEYFP-HA-DAT-WT construct has an N-terminal YFP tag and the HA tag derives 
from modifications of extracellular loop 2, as described elsewhere (Sorkina et al., 
2003a, Sorkina et al., 2006). The presence of YFP- or HA- tag does not interfere 
with expression, function and trafficking of DAT (Sorkina et al., 2006). Cells were 
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lysed using co-IP buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% TritonX-100) 
containing protease inhibitors 48hr post-transfection. Immunoprecipitation was 
performed overnight using goat anti CaMKII antibody (gift from Dr. Roger 
Colbran) and co-immunoprecipitated DAT was visualized using rat anti-DAT 
antibody as for western blots noted above. Mouse anti-CaMKII antibody (1:5000) 
was used to visualize immunoprecipitated CaMKII. Goat IgG was used in parallel 
co-IP experiments to insure specificity of immunoprecipitation.  
DAT-flotillin-1 co-IP 
Flp-in™ HEK stable cells were seeded on 10 cm dishes. Cells were lysed 
using co-IP buffer 48hr after plating. Immunoprecipitation was done using rat 
anti-DAT antibody and co-precipitated flotillin-1 was visualized using a mouse 
anti flotillin-1 antibody (1:1000). Rabbit anti-DAT antibody (1:5000) was used to 
visualize immunoprecipitated DAT. Extracts from Flp-In HEK parent line were 
used as a negative control.  
 
Metabolic labeling to assess DAT phosphorylation 
[32P]orthophosphate metabolic labeling was performed as described 
previously (Bowton et al., 2010). Briefly, Flp-In HEK stable cells transfected with 
either WT DAT or DAT 615C were seeded on 6 well plates and cultured for 
48hrs. Cells were washed once with phosphate free DMEM and incubated in the 
same medium for 1hr pool at 370C to deplete the intracellular ATP. Cells were 
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then supplemented with 1 mCi/ml of [32P]orthophosphoric acid and incubated for 
4hrs at 370C. Cells were then washed 3 times with ice-cold PBS and lysed with 
RIPA buffer containing protease inhibitors and 1 µM okadaic acid and microcystin 
each for 30 min at 40C. Lysates were immunoprecipitated with rat anti-DAT 
antibody overnight at 40C. Immunoprecipitated DATs were visualized using SDS-
PAGE, followed by autoradiography and densitometry. 
 
Cholera toxin B (CTxB) labeling and confocal microscopy 
  HEK 293T cells were plated on glass bottom MatTek plates. Cells were 
transfected with pEYFP-HA-DAT-WT (615R) or pEYFP-HA-DAT 615C 24hrs 
later and cultured for 48 hrs. Cells were washed 3 times with ice-cold PBS 
containing 0.1 mM CaCl2 and 1 mM MgSO4 and incubated with 1 µg/mL Alexa 
647 conjugated CTxB for 30 min at 40C. Cells were washed 3 times with ice-cold 
PBS and fixed using 4% paraformaldehyde for 10 min at room temperature. 
Fixed cells were washed with PBS and stored in PBS until imaging at 40C. 
Confocal imaging was performed in the VUMC Cell Imaging Shared Resource 
(supported by NIH grants CA68485, DK20593, DK58404, HD15052, DK59637 
and EY08126). Laser output was adjusted to assure that all fluorescence 
monitored was non-saturating with respect to fluorophore emission. Intensity 
correlation quotient (ICQ) to assess colocalization of DAT with CTxB labeled 
membranes was obtained as previously described (Steiner et al., 2009, Baucum 
et al., 2010) using the Integration Colocalization Analysis section of WCIF Image 
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J http://www.uhnresearch.ca/facilities/wcif/imagej/. This analysis computes a 
correlation in the intensity of two probes across pixels in regions of interest, with 
ICQ values distributed between -0.5 and +0.5.   ICQ values that report evidence 
for colocalization fall between 0 and + 0.5 and are evaluated for significance 
using a One sample t-test comparing against a zero ICQ value. Genotype 
differences in ICQ values were determined by a two tailed, Studentʼs t-test. 
 
Detection of palmitoylated DAT using click chemistry 
 Flp-in™ HEK stable cells were seeded on 10 cm dishes. 48 hrs. post 
plating cells were serum starved for 1 hr. and metabolically labeled with 17-
octadecynoic acid (17-ODYA) for 6 hrs. at 370C. Cells were then chilled on ice 
and lysed using RIPA buffer. Immunoprecipitation was performed using rat anti-
DAT antibody followed by on-bead, copper-catalyzed click chemistry reaction as 
described elsewhere (Zhang et al., 2010). Briefly, beads were resuspended in 
20μL of PBS and 2.25 μL freshly premixed click-chemistry reaction mixture 
biotin-azide (100 μM, 5 mM stock solution in DMSO), Tris(2-
carboxyethyl)phosphine hydrochloride (TCEP) (1 mM, 50 mM freshly prepared 
stock solution in deionized water), Tris[(1-benzyl-1H-1,2,3-triazol-4-
yl)methyl]amine (TBTA) (100 μM, 2mMstock solution in 1:4 DMSO:t-butanol) and 
CuSO4·5H2O (1 mM, 50 mM freshly prepared stock solution in deionized water)] 
for a total approximate reaction volume of 25 μL for 1 h at room temperature. The 
beads were washed three times with 1 mL of ice-cold RIPA buffer and bound 
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proteins were eluted using LSB followed by SDS-PAGE and transfer onto PVDF 
membrane. Attachment of 17-ODYA (palmitoylation mimic) was confirmed using 
western blot with streptavidin-HRP(1:1000). The same membrane was stripped 
and reprobed for DAT using rabbit anti-DAT antibody.   
 
Detection of AMPH using High-Pressure Liquid Chromatography (HPLC) 
Flp-In HEK cells were seeded in 6 well plates and incubated for 36-48hrs 
before experiments. Cells were washed twice with warm KRH buffer before 
incubation with 10 µM AMPH for 5 minutes at 370C. Cells were rapidly washed 3 
times using ice-cold KRH buffer and lysed using 10 mM TRIS/1 mM EDTA, pH 
8.0 buffer (TE) containing protease inhibitors. Total protein concentration was 
determined using BCA protein assay and used to normalize the AMPH uptake. 
AMPH uptake was determined using HPLC analysis and data are expressed as 
nmol AMPH transported per µg protein.  
 
Amperometry  
Unpatched amperometric currents were recorded as previously 
described(Bowton et al., 2010) using Flp-In™ HEK stable cells. Briefly, cells were 
plated at a density of 103 per 35-mm culture dish.  To preload cells with DA, 
attached cells were washed with KRH assay buffer containing 10 mM D-glucose, 
100 µM pargyline, 1 mM tropolone, and 100 µM ascorbic acid, and then 
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incubated with 1 µM DA in assay buffer for 20 min at 37°C.  Dishes containing 
DA loaded cells were then washed three times with external solution (130 mM 
NaCl, 10 mM HEPES, 34 mM D-glucose, 1.5 mM CaCl2, 0.5 mM MgSO4, 1.3 mM 
KH2PO4, adjusted pH to 7.35, and 300 mOsm).  A carbon fiber electrode 
(ProCFE; fiber diameter of 5 µm; obtained from Dagan Corporation), juxtaposed 
to the plasma membrane and held at +700 mV (a potential greater than the 
oxidation potential of DA), was used to monitor basal and AMPH-evoked DA 
efflux through DAT as a consequence of DA oxidation. To determine basal DAT-
dependent efflux, cells were treated with 10 µM cocaine following establishment 
of a stable recording baseline.  Cells were not voltage-clamped in basal or AMPH 
(10 µM)-evoked DA efflux experiments.  Amperometric currents in response to an 
addition of AMPH were recorded using an Axopatch 200B amplifier (Molecular 
Devices, Union City, CA) with a low-pass Bessel filter set at 1 kHz. Traces were 
digitally filtered offline at 1 Hz using Clampex9 software (Molecular Devices).  DA 
efflux was quantified as the mean peak amperometric current (in picoamperes)  
+/- SEM. 
 
Quantification and statistics 
Western blots were quantified using NIH Image J software, with multiple 
exposures taken to insure linearity of signal detection. Studentʼs t-test or one-way 
ANOVA with Bonferroniʼs post hoc test was used wherever appropriate. 
GraphPad Prism was used to determine Vmax and Km for saturation kinetic 
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analyses and IC50 for inhibition analyses. Significant differences between DAT 
615R and 615C values of Vmax, Km, and IC50 were determined using Studentʼs t-





	   58	  
Chapter III 
 
Altered Regulation and Trafficking Associated with the ADHD-Associated 
Human DAT Variant R615C 
 
Introduction 
 The neurotransmitter DA provides critical modulatory influences over 
circuits subserving reward, locomotor activity, and attention (Carlsson, 1987, 
Robbins, 2003). As such, alterations in DA signaling contribute to multiple 
neurological and psychiatric disorders including Parkinsonʼs disease (Chase et 
al., 1998), attention-deficit hyperactivity disorder (ADHD) (Mazei-Robison et al., 
2005), and addiction (Ritz et al., 1987). The re-uptake of DA through presynaptic 
DATs is a primary mechanism for terminating DA action at presynaptic and 
postsynaptic receptors and is a major target for psychostimulants, such as 
cocaine and AMPH.  
 Multiple studies point to a contribution of variation in the genes encoding 
DAT, catechol-O-methyl transferase (COMT) and/or DA receptors as influencing 
risk for ADHD (Gill et al., 1997, Qian et al., 2003, Bobb et al., 2005, Mazei-
Robison et al., 2005), the most commonly diagnosed disorder of school age 
children in the U.S. A further link between DAT function and ADHD is suggested 
from the therapeutic utility of DAT-interacting psychostimulants, including 
methylphenidate (Ritalin®) and AMPH preparations (e.g. Adderall®). Brain 
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imaging studies also point to deficits in DA signaling as a key feature of ADHD 
(Swanson et al., 2007). Genetic elimination of DAT expression in mice reduces 
presynaptic DA stores, elevates extracellular DA, and produces hyperactivity in a 
novel environment (Giros et al., 1996). However, humans that are homozygous 
for loss of function DAT (SLC6A4) alleles exhibit infantile neonatal dystonia 
rather than ADHD (Kurian et al., 2009), raising questions as to the relevance of 
compromised DAT function and DA signaling as a key feature in ADHD.  
 Reasoning that genetic alterations that perturb DAT regulation, as 
opposed to DAT elimination, could reconcile data from rodent and human 
studies, we screened ADHD subjects for rare variation producing coding variation 
in DAT. Previously, we described the anomalous, non-vesicular release of DA by 
the DAT A559V coding variant (Mazei-Robison et al., 2008), leading to the 
hypothesis that dysregulated DA availability may be a determinant of risk for 
ADHD. Here we provide additional evidence for this idea through study of the 
properties of a second DAT variant, R615C. 
 Before presenting the results obtained through a characterization of the 
DAT-R615C variant (DAT 615C), I wish to highlight the evidence from the 
literature that indicate common regulatory pathways linked to the WT (DAT 615R) 
transporter. Earlier I described in detail the effects of alterations in intracellular 
signaling on DAT 615R.  Here, I summarize findings pertinent to studies 
described in this chapter. Acute treatment with β-PMA (200nM, 30 minutes), 
leads to a reduction in DA uptake activity and a loss of DAT from the plasma 
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membrane (Huff et al., 1997, Loder and Melikian, 2003, Sorkina et al., 2005). 
Recently, Cremona and colleagues presented evidence that PKC-induced loss of 
surface DAT occurs through flotillin-1 enriched membrane rafts (Cremona et al., 
2011), a finding previously reported to occur via clathrin-mediated mechanism 
(Sorkina et al., 2005). The data presented in this thesis are consistent with a 
membrane raft-mediated internalization mechanism subserving regulated DAT 
trafficking. Acute AMPH treatment has been shown to produce flotillin-1- and 
CaMKII-dependent DA efflux (Fog et al., 2006, Cremona et al., 2011), to reduce 
DA transport activity, and to increase DAT endocytosis (Wei et al., 2007b, Chen 
et al., 2010). In this chapter, I describe the results I obtained from studies that 
compare the alterations between DAT 615R and DAT 615C with β-PMA and 




Identification of a functional DAT coding variant in an ADHD subject 
Using polymorphism discovery methods (Li et al., 2002), we screened coding 
exons and intron-exon junctions of the SLC6A4 gene in 417 ADHD subjects. 
Although a number of variants have been identified that alter the coding of DAT, 
all known variants are rare (allele frequency <1%) (Mazei-Robison et al., 2005). 
In an Irish cohort of 100 subjects receiving a DSM-IV diagnosis of ADHD 
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(Bellgrove et al., 2009), we identified a nonsynonymous, single nucleotide 
polymorphism (SNP, 2026 T/C) that converts a highly conserved Arg residue at 
position 615 to Cys (R615C). R615 is completely conserved in mammalian DATs 
and resides in a generally well-conserved region of the DAT C-terminus (Figure 
5), a region implicated in transporter somatic export, surface trafficking and 
protein-protein interactions (Torres et al., 2001, Bjerggaard et al., 2004, Fog et 
al., 2006). The subject, a Caucasian male of European origin and heterozygous 
for the R615C variant was 13 years old at the time of assessment and possessed 
a strong clinical and research diagnosis of combined-type ADHD (Connorʼs 
parent rating scale-inattentive symptoms, T=70; hyperactive symptoms, T=75, 
total score=74, WISK-III UK IQ=141). Pedigree genotyping revealed that the 
mutation was transmitted from the probandʼs mother who is retrospectively 
suspected to have suffered from ADHD as a child (Wender-Utah=59), although 
Figure 5 Sequence Alignment and Pedigree Analysis of DAT 615C: (A) Sequence alignment 
showing conservation of Arg 615 across mammalian DATs. (B) Pedigree of the ADHD proband 
carrying the R615C variant. The subject (black box) is heterozygous for the R615C-DAT variant. 
Transmission of the mutant allele occurred from mother (grey circle). Other family members 
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no clinical diagnosis is currently available. The subjectʼs father and two older 
sisters, who do not carry the variant, are unaffected (Figure 5). The R615C 
proband has been successfully treated with methylphenidate. 
 To search for functional evidence that the R615C variant may be causal in 
the probandʼs ADHD, we compared the activities of DAT 615R and DAT 615C in  
 
stably transfected HEK cells. To limit confounds associated with different sites of 
integration, we created stable Flp-In™ HEK lines that express either of the two 
transporters from a common locus, under the control of the same promoter 
(Sauer, 1994).  Saturation kinetic analysis revealed a significant reduction in DA 
transport Vmax for the R615C variant (615R, 1.6±0.2 vs. 615C, 1.0±0.1 pmol/μg 
protein/min, P<0.005, two-tailed Studentʼs t-test) without a significant change in 
DA KM (1.3±0.4 vs. 1.0±0.3 μM) (Figure 6). 
Figure 6 DA Transport Saturation Kinetic Analysis: DA transport Vmax and Km are expressed 
as pmol/μg protein/min and μM respectively. Data derive from a nonlinear, single-site curve fit to 
n=3 saturation kinetic assays with error bars indicating the SEM at each concentration. 
 
	   63	  
 The reduced DA transport capacity was associated with a reduction in 
steady-state DAT protein levels (86±3% of DAT 615R; n=6, P<0.005, two-tailed 
Studentʼs t test) and an even greater loss of transporter surface transporter 
expression (50±7% of DAT 615R; n=6, P<0.0001, two-tailed Studentʼs t test) 
(Figure 7), the latter determined by whole-cell biotinylation. However, we 
observed no significant differences in the IC50 values for cocaine (615R, 7.7±2.0 
vs. 615C, 10.0±2.1 nM), GBR 12909 (615R, 9.7±3.0 vs. 615C, 10.9±2.0 nM), or 
AMPH (615R, 329±135 vs. 615C, 226±101 nM). We did find a small, but 
statistically significant loss of potency for methylphenidate (615R 585±290 vs. 
615C, 821±160 nM, P<0.05, two-tailed Studentʼs t-test). Thus, although surface 
levels and DA transport capacity are reduced, DAT 615C appears to exhibit 
comparable interactions with DA and DAT antagonists as seen with DAT 615R. 
 
Figure 7 Analysis of Total and Surface DAT Protein: Left: Representative western blot 
showing reduction in the total and surface DAT for the R615C variant compared to 615R. Total 
protein levels of β-actin, an intracellular loading control, were similar for both 615R and 615C. 
Right: Quantification from six independent experiments +/- SEM, indicating a significant reduction 
in the R615C variant compared to 615R for both total and surface expression. In the blot shown, 
total protein samples were diluted 5 fold compared to the surface protein fraction to retain signal 
linearity 
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Anomalous modulation of DAT 615C by AMPH   
AMPH produces two alterations in DAT-expressing cells (Sulzer et al., 2005). 
First, AMPH induces (sec-min) non-vesicular DA release (efflux), mediated by 
reverse transport of cytoplasmic DA that is supported by CaMKII-mediated 
phosphorylation of the DAT N-terminus (Khoshbouei et al., 2003, Fog et al., 
2006). Second, AMPH treatment of DAT-expressing cells has been reported to 
produce both a rapid translocation of the transporter to the cell surface (Furman 
et al., 2009a), with more prolonged treatments (10-30 min) producing net 
transporter internalization (Chen et al., 2010). Using carbon fiber amperometry 
(Bowton et al., 2010), we monitored basal efflux from DAT 615R and DAT 615C 
Figure 8 Amperometric Detection of Basal DA Efflux: DA preloaded Flp-In HEK stable cells 
display no significant differences in basal DA efflux between DAT 615R and DAT 615C (n=5, 
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cells that were preloaded with DA (Figure 8). We found no significant difference 
in DA efflux comparing WT and mutant transporters. 
 We also monitored AMPH-triggered DA efflux from DA-preloaded cells 
and, as shown in Figure 9A, 615R and 615C-expressing cells exhibited 
comparable AMPH-evoked DA efflux, measured using the peak amplitude of 
amperometric responses. This finding was surprising due to the reduced steady-
state DAT surface expression of the R615C variant noted above. Indeed when 
we normalized the AMPH-induced DA efflux to respective DAT surface 
expression, a significantly greater DA efflux was detected from DAT 615C 
expressing cells (Figure 9B). Since it was not possible to obtain DA efflux and 
surface expression from the same experimental setup no further statistical 
analysis was performed on the data. We found a possible answer to this 
conundrum in examining the impact of AMPH on transporter surface expression. 
Figure 9 AMPH-induced DA Efflux: (A) Flp-In 293 stable cells were preloaded with 1 μM DA for 
20 min and AMPH-induced DA efflux was measured using carbon fiber amperometry. AMPH-
induced DA efflux from DAT 615C was not significantly different than 615R (1.0±0.22 pA for 615R 
vs. 0.996±0.18 pA for 615C). (n=5, P>0.05, Studentʼs t-test) Data was collected by Peter 
Hamilton. (B) AMPH-induced DA efflux from DAT 615C was ~ 2 times more when the efflux was 
normalized to the respective surface expression. 	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Whereas treatment of 615R expressing cells with 10 μM AMPH for 30 min 
produced the expected reduction in transporter surface expression, without any 
change total DAT protein levels (Figure 10), the same treatment failed to reduce 
surface expression of DAT 615C.  
 Consistent with these findings, AMPH reduced DA transport from DAT 
615R cells, but not from DAT 615C cells (Figure 11). Equivalent findings were 
also obtained following transient transfection of DAT 615R or DAT 615C into 
HEK-293T cells (data not shown) or CAD cells, a catecholamine-producing 
neuronal cell line (Qi et al., 1997) (Figure 12). 
 DAT internalization is known to occur following activation of PKC, by 
phorbol esters such as β-PMA (Loder and Melikian, 2003). As shown in Figure 
13, we found that unlike DAT 615R, DAT 615C displayed no net endocytosis 
Figure 10 Effect of AMPH DAT Surface Expression: Left: Representative western blot 
showing total and surface DAT protein levels with or without AMPH treatment (10 μM, 30 
minutes) Right: Quantification of AMPH-induced decrease in DAT surface protein levels 
expressed as surface/total. Data were normalized to basal DAT surface/total expressions as 
100%. AMPH treatment caused a significant (62±7%) decrease in DAT 615R surface expression 
whereas no change was detected in 615C expression (95±8%). Significant differences were 
calculated using Sstudentʼs t-test. (n=7, P<0.0001) 
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(109±9% of vehicle treated cells) and, consistent with this finding, also displayed 
no reduction in DA transport activity (98±2% of control), following β-PMA 
treatment (200 nM, 30 min). On the other hand, similar β-PMA treatments caused 
internalization of DAT 615R (72±4% of vehicle treated cells, P<0.005, two-tailed 
Studentʼs t-test) and a significant reduction in DA transport activity (61±6% of 
control, P<0.001, two-tailed Studentʼs t-test) 
 AMPH transport is required to modulate DAT trafficking as demonstrated 
by studies of a transport incompetent DAT mutant. (Kahlig et al., 2006). 
Intracellular injection of AMPH, however, produces internalization of this mutant, 
suggesting that intracellular AMPH activates signaling pathways sufficient to 
produce DAT internalization. Thus, the R615C variant could transport AMPH 
more efficiently than wildtype DA, leading to the appearance of equivalent DA 
Figure 11 Effect of AMPH DA Uptake Activity: AMPH-mediated (10 μM, 30 minutes) reduction 
in the DA transport seen in DAT 615R (white bar; AMPH) versus 615C (black bar; AMPH). Basal 
DA transport levels of each cell lines were used to normalize AMPH-mediated reductions. AMPH 
caused a significant decrease (66±5 % of basal) in the DA transport of DAT 615R whereas no 
significant changes were detected for 615C (93±6 % of basal). Significant differences were 
calculated using Studentʼs t-test. (n=3, P<0.001) .  
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efflux despite reduced surface expression. However, HPLC assays of DAT 615C 
cells treated with AMPH under the same conditions used for efflux assays 
revealed similar levels of intracellular AMPH for DAT 615R and DAT 615C cells 




Figure 12 Effect of AMPH on DA uptake and DAT surface expression in transiently 
transfected CAD cells: (A) Basal DA transport levels were normalized to respective cell lines 
and AMPH-mediated reductions were calculated. AMPH caused a significant decrease (72±4 % 
of basal) in the DA transport of DAT 615R whereas no significant changes were detected for 
615C (93±9 % of basal). Significant differences were calculated using one-way ANOVA followed 
by Bonferroniʼs post hoc test. (n=4, P<0.01) (B) Left: Representative western blot showing 
surface DAT protein levels after AMPH treatment (10 μM, 30 minutes).  Right: Quantification of 
AMPH-induced decrease in DAT surface levels, expressed as surface/total. Data is normalized to 
basal DAT surface/total expressions as 100%. AMPH treatment caused a significant (63±6%) 
decrease in the DAT 615R expression while no change was detected in 615C expression 
(104±9%). Significant differences were calculated using Studentʼs t-test. (n=4, P<0.0001).  
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DAT R615C exhibits accelerated rates of constitutive endocytosis and 
recycling. 
 To define the mechanisms supporting loss of AMPH-induced surface 
trafficking of the DAT R615C variant, we implemented kinetic surface 
biotinylation assays that report rates of membrane protein endocytosis and 
recycling (Deken et al., 2003, Holton et al., 2005). By monitoring the amount of 
surface biotinylated DAT that displays resistance to a biotin-stripping reagent, we 
can quantify the extent of transporter internalization under basal and AMPH-
treated conditions.   Here, we discovered that the DAT R615C variant displays an 
accelerated, constitutive internalization rate relative to the wildtype transporter 
(Figure 14). Moreover, whereas AMPH significantly increased the rate of 
Figure 13 Effect of β-PMA on DA Uptake and DAT Surface Expression in Flp-In HEK Cells: 
(A) Data are normalized to vehicle treatments for individual cell lines. β-PMA caused a significant 
decrease (61±6 % of veh.) in the DA transport of DAT 615R while no significant changes were 
detected for 615C (95±5 % of veh.). Significant differences were calculated using one-way 
ANOVA followed by Bonferroniʼs post hoc test. (*p< 0.01; n=3) (B) Left: Surface DAT protein 
level after β-PMA treatment (200 nM) for R615C variant is significantly greater than DAT 615R 
protein level. Right: Data is normalized to vehicle treated DAT 615R surface/total expressions as 
100%. β-PMA treatment caused a significant (72±4%) decrease in the DAT 615R expression 
while no change was detected in 615C expression (119±9%). Significant differences were 
calculated using Studentʼs t-test. (*p<0.05; n=3) 
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internalization for DAT 615R, we observed no change in DAT 615C 
internalization rate over that seen under basal conditions.  
 Possibly, accelerated internalization of DAT 615C under basal conditions 
explains this transporterʼs significantly diminished basal surface expression. 
Alternatively, a change in surface recycling could also explain this difference, and 
also account for insensitivity to AMPH. We therefore determined the extent of 
DAT 615R and 615C recycling by biotinylating the full pool of recycling 
transporter molecules at 370C, followed by stripping away any surface resident 
transporters at 40C. Upon warming the cells back to 370C, we determined the 
rate of reappearance of either wildtype or DAT 615C. Thirty minutes after 
stripping and shifting back to 370C, approximately 40% of wildtype DAT remained 
intracellular under basal conditions, and the extent of recycling was not further 
decreased by AMPH.  In contrast, approximately 90% of the DAT R615C variant 
Figure 14 Accelerated constitutive Endocytosis Associated with DAT 615C: Left: 
Representative western blot showing increased basal endocytosis associated with the R615C 
variant. AMPH treatment (10 μM, 30 minutes). Right: Quantification of internalization rates 
normalized to stripping efficiency. Basal internalization rate of DAT 615C was significantly 
increased compared to 615R (16.7±0.9% for 615C vs. 8.5±1.8% for 615R; n=3, P<0.05, Studentʼs 
t test). AMPH treatment significantly increased internalization rate of DAT 615R (8.5±1.8% for 
basal vs. 18±2.6% for AMPH; n=3, P<0.05, Studentʼs t test) without affecting the R615C variant 
(16.7±0.9% for basal vs. 16.3±2.9% for AMPH; n=3, P>0.05, Studentʼs t test).  
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recycled under basal conditions. This capacity for recycling was also not 
diminished by AMPH (Figure 15). Thus, AMPH treatment produced a net 
internalization of wildtype DAT protein by enhancing transporter endocytosis 
rates without a compensatory increase in recycling rates. DAT 615C 
constitutively endocytosis and recycles at a much faster rate than wildtype 
transporters, and this difference is not impacted by AMPH treatment. Thus, the 
failure of DAT 615C to exhibit AMPH-triggered internalization and a 
commensurate reduction in DA uptake is most consistent with the transporterʼs 
efficient recycling through a pathway that cannot support acceleration of 
trafficking rates, which are already elevated.  
Figure 15 DAT 615C Exhibits Accelerated Recycling: Left: Representative western blot 
showing accelerated recycling of R615C variant. AMPH treatment (10 μM, 30 minutes) did not 
impact the recycling rate for both DAT 615R and 615C. Right: Quantification of recycling rate 
normalized to intracellular DAT fraction. A bigger fraction of DAT still remains intracellularly after 
constitutive recycling for DAT 615R compared to 615C (42.9±8% for 615R vs. 11.2±2.3% for 
615C; n=6, P<0.005, Studentʼs t test).  AMPH treatment did not alter fractional DAT remaining 
inside after recycling (basal-42.9±8% vs. AMPH-43.4±11.7% for DAT 615R and basal-11.2±2.3% 
vs. AMPH-14.8±4.1% for DAT 651C; n=3-6, P>0.05, Studentʼs t test).    
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Discussion 
 ADHD is the most commonly diagnosed disorder of childhood (Smith et 
al., 2009). Multiple lines of evidence, noted in Chapter I, suggest that alterations 
in DA signaling, including changes in DAT expression or function (Mazei-Robison 
et al., 2005), can increase risk for the cognitive and hyperactive perturbations 
found in ADHD. In a meta-analysis of association studies examining SLC6A4 
polymorphisms in ADHD, Gizer and colleagues concluded that the locus is likely 
to harbor multiple functional variants whose variable influence across families 
can account for differences in effect sizes detected (Gizer et al., 2009).  To date, 
however, the majority of genetic studies implicating DAT gene variation with 
ADHD, or the efficacy of ADHD medications, derive from analysis of a variable 
number tandem repeat (VNTR) in the 3'-untranslated region. As the functional 
impact of this VNTR remains ill defined (Winsberg and Comings, 1999, Kirley et 
al., 2002, Kirley et al., 2003), aligning these studies with specific alterations in DA 
signaling is difficult. Rather than focus on common DAT variation of uncertain 
impact, we sought insights into the DA contributions to ADHD via a search for 
highly penetrant, DAT coding variants. Studies of rare, heritable forms of 
Alzheimerʼs disease (Lemere et al., 1996) and Parkinsonʼs disease (Groen et al., 
2004) provide cogent examples of how the elucidation of rare gene variation can 
lead to novel pathophysiological concepts. Moreover, intensive study of rare 
variants is justified as such studies can help define broader networks that may 
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elucidate a common underlying pathophysiology (Abrahams and Geschwind, 
2010). 
 Recently, we described properties of the DAT coding variant, A559V, 
identified in two male siblings with ADHD (Mazei-Robison et al., 2005). We 
observed that A559V displays increased DAT channel activity and spontaneous, 
nonvesicular DA release that can be greatly enhanced by membrane 
depolarization (Mazei-Robison et al., 2008, Bowton et al., 2010). Moreover, 
spontaneous DA efflux can be attenuated by the ADHD therapeutic AMPH. Here, 
we describe a second, rare, ADHD-associated DAT coding variant, R615C, 
where substitution establishes profound basal and regulatory alterations. 
Although the pedigree harboring the R615C variant is small, with only a single 
affected carrier, the regulatory disruption we report provides further evidence that 
changes in DAT-dependent DA signaling contributes to risk for ADHD. Studies 
with knock-in mice that harbor the R615C variant, similar to those underway in 
our lab involving the A559V variant (Mergy M.A. and Blakely R.D., unpublished 
observations) should allow us to assess which of the multiple in vitro alterations 
in trafficking and regulation we have identified occurs in vivo, and how these or 
other changes impact synaptic DA inactivation. 
 Multiple elements of DATʼs cytoplasmic N- and C-termini have been 
implicated in basal and regulated control of DAT surface expression, stability and 
activity. The DAT N-terminus has been the focus of much investigation that 
examines AMPH-induced DA efflux (Khoshbouei et al., 2004, Fog et al., 2006, 
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Binda et al., 2008). In contrast, Holton and colleagues have proposed that 
sequences in the DAT C-terminus (residues 587-596) influence basal and PKC-
modulated transporter trafficking (Holton et al., 2005). The distal C-terminus 
(residues 618-620) bears a type II PDZ domain interaction motif that has been 
shown to dictate interactions of the transporter with the PDZ domain protein, 
PICK1, and possibly enhance DAT surface expression (Torres et al., 2001). 
Interestingly, Bjerggaard and colleagues found that substitution of AAA for the 
RHW sequence immediately upstream of the PDZ recognition motif leads to ER 
retention, but preserves the ability of mutant DAT to bind PICK1 (Bjerggaard et 
al., 2004). The R615C mutation lies in the RHW sequence, and thus an effect on 
ER/Golgi export may contribute to the transporterʼs reduced surface expression 
and DA transport Vmax. As previously reported, we found AMPH treatments 
produce net transporter endocytosis (Saunders et al., 2000, Kahlig et al., 2004, 
Boudanova et al., 2008a). Activation of PKC isoforms with β-PMA also induces 
net transporter internalization (Miranda et al., 2007, Boudanova et al., 2008b, 
Cremona et al., 2011), an effect proposed to be mediated by DAT C-terminal 
sequences (Holton et al., 2005). Remarkably, we found that the R615C variant 
demonstrates complete resistance to the trafficking effects of both AMPH and 
PKC activation. These findings led us to monitor the kinetics of DAT 615C basal 
and regulated surface trafficking. We found that DAT 615C displays a 
significantly accelerated rate of both endocytosis and recycling as compared to 
wildtype DAT. In our cells, treatment with AMPH accelerates the endocytic rates 
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of wildtype DATs, with no detectible change in transporter recycling. Thus, it 
seems likely that DAT 615C lacks the dynamic range needed to display regulated 
endo/exocytosis due its high rate of constitutive trafficking. 
 Alterations in basal, as well as AMPH- and β-PMA-induced trafficking 
suggest that the response of DAT 615C to intracellular signaling mechanisms are 
perturbed, either due to an inaccessibility of transporters to critical proteins 
controlling endocytosis through regulated pathways or a mislocalization of 
transporters to compartments that do not support regulated endocytosis, or both. 
In the next chapter, I describe studies that establish a novel role of CaMKII to 
support DAT 615C activity, along with changes in the mutant transporterʼs 
membrane microdomain association. 
	   76	  
Chapter IV 
 
Role of Signaling Pathways, Microdomains, and the C-Terminus in the 
Altered Behavior of DAT 615C 
 
Introduction 
 Our initial characterization of the DAT R615C variant indicated a reduced 
basal DA transport Vmax, a decreased basal total and surface protein expression, 
a lack of β-PMA and AMPH-mediated downregulation of transport activity and 
endocytosis, and accelerated basal trafficking. In this chapter, I report on my 
efforts to delineate mechanisms underlying the lack of AMPH actions on the DAT 
615C variant. By way of introduction to these studies, I discuss aspects of 
AMPH-induced changes in signaling pathways that support the psychostimulantʼs 
actions to produce DA efflux and DAT trafficking. 
 AMPH is a DAT substrate and thereby uses DAT to enter the intracellular 
environment, although at high concentrations AMPH can also enter cells in a 
DAT-independent manner (Jones et al., 1998, Sulzer et al., 2005). Since AMPH 
is a weak base with the ability to be concentrated in synaptic vesicles by VMAT 
proteins, the psychostimulant also depletes synaptic vesicles of DA by 
dampening the vesicular proton gradient. AMPH also causes an increase in 
intracellular Ca2+ (Gnegy et al., 2004) that in turn activates CaMKII and promotes 
CaMKII-dependent DA efflux (Fog et al., 2006). With more prolonged exposure 
(10-30 min), AMPH produces DAT downregulation via a clathrin-mediated 
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endocytosis of surface transporters and a consequent reduction in DA transport 
activity (Saunders et al., 2000). Whether AMPH-dependent DAT internalization is 
dependent on CaMKII activity is unknown.  
 Physical association between DAT and CaMKII takes place via a three 
amino acid motif (RHW; amino acids 615-617) in the distal C-terminus domain of 
DAT and mutating these residues to alanine leads to loss of CaMKII association 
as well as AMPH-mediated DA efflux.   Since DAT 615C lies in this motif, we 
speculated that altered CaMKII association could accompany or underlie the lack 
of AMPH action in producing net endocytosis of the mutant transporter and 
performed experiments to address these possibilities. Recently, Cremona and 
colleagues also showed that flottilin-1 interaction is essential for AMPH-mediated 
DA efflux, a CaMKII-dependent phenomenon. As such, I sought to investigate 
whether changes in flotillin-1/DAT 615C association. Finally, I sought to 
determine whether it is the loss of Arg per se or the conversion of Arg to Cys, or 
both, that renders the DAT 615C insensitive to AMPH treatment.  
 
Results 
DAT 615C exhibits a CaMKII-dependent state of functional inactivation. 
  AMPH acts to mobilize intracellular Ca2+, which leads to CaMKII activation 
(Gnegy et al., 2004, Wei et al., 2007a). Ca2+ mobilization and CaMKII activation 
have been shown to be critical for AMPH evoked DA efflux, likely through 
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phosphorylation of the DAT N-terminus(Khoshbouei et al., 2004, Fog et al., 
2006). Most relevant to my trafficking studies, CaMKII inhibition has been shown 
to preclude AMPH-mediated DAT, net surface redistribution (Wei et al., 2007a). 
Since DAT 615C effluxes DA in response to AMPH, yet fails to traffic, I 
investigated whether CaMKII/DAT interactions that depend on residues 615-617, 
remain intact (Fog et al., 2006). As shown in Figure 16, we detected an ~2 fold 
increase in recovery of DAT 615C/CaMKII vs. 615R/CaMKII complexes. Since 
published data is most consistent with CaMKII phosphorylation of DAT N-
terminal Ser residues, after binding to the DAT C-terminus results in (Fog et al., 
2006), I asked whether the increased CaMKII association of the R615C variant is 
Figure 56 Increased Basal CaMKII Association of the R615C Variant: Left: Representative 
western blot showing increased association between DAT 615C and CaMKII compared to 615R. 
Right: Quantification of DAT co-IP with CaMKII normalized to respective inputs. Significantly 
larger pool of 615C is co-precipitated with CaMKII (179±26 % of 615R; n=3, P<0.05, Studentʼs t 
test). 
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paralleled by increased transporter phosphorylation. Indeed, immunoprecipitation 
of DAT 615R or 615C from [32P]orthophosphate labeled cells, when data were 
normalized by total protein input, revealed a significantly increased basal 
phosphorylation of the R615C variant (Figure 17). Given that, in the stable cell 
lines used, total DAT 615C protein levels are modestly but significantly reduced 
when compared to total WT DAT protein, the elevation in DAT 615C 
phosphorylation is likely to be actually somewhat higher than illustrated. If 
CaMKII phosphorylates DAT at the cell surface only, the more substantial loss in 
DAT 615C surface expression argues that CaMKII phosphorylation of DAT may 
be even more elevated. 
Figure 17 Increased Basal Phosphorylation of the R615C Variant: Top: Representative 
autoradiograph indicating increased basal phosphorylation of DAT 615C compared to 615R 
Bottom: Quantification of DAT bands from the autoradiograph showing significant increase in 
basal phosphorylation levels of DAT 615C (125±1.6 % of 615R; n=3, P<0.05, Studentʼs t test). 
Equal total protein amounts were used for IP following the metabolic labeling.  
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 To assess whether the increased CaMKII association and basal 
phosphorylation associated with the DAT 615C variant has functional 
consequences, we treated DAT 615R or 615C cells with the CaMKII inhibitor KN-
93, either during AMPH treatments, or as a pretreatment before AMPH addition. 
Treatment of cells with KN-93 alone failed to impact the DA transport activity of 
DAT 615R cells (Figure 18A). However, the same treatment blocked the 
reduction imposed on DA transport activity by AMPH treatment. As shown above, 
AMPH imposed no significant effect on DA transport activity for DAT 615C cells 
(Figure 18A).  Surprisingly, KN-93 alone significantly decreased the DA transport 
activity of 615C cells, and this effect was even more pronounced when KN-93 
was combined with AMPH. The specificity of these drug treatments was 
confirmed through the use of KN-92, a structural analog of KN-93 that does not 
inhibit CaMKII (Figure 18B).  These data are consistent with the hypothesis that 
excessive, constitutive CaMKII regulation of DAT 615C produces a shift of DAT 
proteins to AMPH-insensitive endocytosis and recycling pathways. In support of 
this idea, biotinylation studies demonstrated that CaMKII blockade with KN-93 
antagonized AMPH-induced reductions in cell surface levels of wildtype DAT 
(Figure 19), similar to its ability to block AMPH-induced reductions in DA uptake. 
In contrast, and distinct from its effect on DA uptake, KN-93 treatment of DAT 
615C cells produced did not reverse AMPH-induced transporter internalization 
(Figure 19). These unexpected data reveal a CaMKII-dependent capacity for 
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modification of DA transport function specific to DAT 615C that occurs in a 
trafficking-independent manner.   
The ability of CaMKII to enhance DAT 615C DA transport activity could arise 
from either a shift of transporters to higher affinity DA recognition or from a 
concentration-independent increase in DA transport capacity. To address these 
Figure 18 Effect of KN-93 and KN-92 on AMPH-mediated DA Transport Reduction: (A) KN-
93 (1 µM, 30 minutes) treatment  (black bar, KN-93) caused a significant reduction in the DA 
activity of DAT 615C (79±4% of basal) whereas no effect was seen with the same treatment of 
DAT 615R (white bar, KN-93, 95±9% of basal). Pretreatment with KN-93 before AMPH (10 µM, 
30 minutes) addition blocked the AMPH-mediated reduction in DA transport of DAT 615R (white 
bars, AMPH (70±4%) vs. KN-93+AMPH (98±10%)) whereas DAT 615C showed a further, 
significant reduction in transport activity (black bars, AMPH (89±3%) vs. KN-93+ (63±5%)). The 
DA transport reduction upon KN-93+AMPH treatment was not significantly different from the 
reduction obtained by treatment with KN-93 alone in the R615C variant (79±4% for KN-93 vs. 
63±5% for KN-93+AMPH). Data were normalized to basal DA uptake of respective cell lines. 
Significant differences were calculated using one-way ANOVA followed by Bonferroniʼs post hoc 
test. (n=3-6, P<0.0001) (B) The inactive analog of KN-93, KN-92 did not affect DA uptake in 
either DAT 615R (white bar, KN-92; 102±10% of basal) or 615C (black bar, KN-92; 108±12%of 
basal). Pretreatment with KN-92 (1 µM, 30 minutes) also did not block the AMPH-mediated (10 
µM, 30 minutes) DA transport reduction in DAT 615R (white bar, KN-92+AMPH, 65±8% of basal) 
and had no effect on 615C (black bar, KN-92+AMPH, 90±7% of basal). Data were normalized to 
basal DA uptake of respective cell lines. Significant differences were calculated using one-way 
ANOVA followed by Bonferroniʼs post hoc test. (n=3, P<0.05) 
 
	   82	  
possibilities, we conducted saturation kinetic analysis for the DAT R615C variant, 
in the presence or absence of KN-93+AMPH (Figure 20). These drug treatments 
produced no significant change in DA transport Km (basal, 5.4±1.5 vs. KN-
93+AMPH, 3.8±0.6 µM), but generated a significant reduction in DA transport 




These findings reveal that CaMKII activity is required to sustain R615C in an 
active state. In the absence of CaMKII activity, DAT 615C switches to a state 
Figure 19 Effect of KN-93 on AMPH-induced DAT Internalization: Top: Representative 
western blot showing KN-93+AMPH treatment reduction in DAT surface levels for both DAT 615R 
and 615C. Bottom: Quantification showing KN-93+AMPH (1 µM KN-93 for 30 minutes followed 
by 10 µM AMPH for 30 minutes) treatment rescued the reduction in the DAT surface expression 
of DAT 615R  (101±7% of basal) similar to results obtained in DA uptake assays. KN-93+AMPH 
treatment showed no change (113±10% of basal) in the surface levels of DAT 615C. The 
differences obtained from the KN-93+AMPH treatment were not statistically significant from their 
basal correlates assessed by Studentʼs t-test. (n=7, P>0.05) 
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DAT 615C demonstrates altered localization to membrane microdomains. 
As noted above membrane microdomains have been reported to 
associate with and influence DAT conformations, to constrain DAT lateral 
mobility, to be required for PKC-mediated internalization, and to dictate CaMKII-
mediated DA efflux. DAT has also been shown to localize to membrane 
microdomains that are enriched for the protein flotillin-1. Our co-
immunoprecipitation studies revealed reduced levels of flottilin-1 in extracts of 
cells stably transfected with DAT 615C as compared to extracts from cells 
transfected with DAT 615R (Figure 21). Since reduced association of flotillin-1 
could reflect diminished surface expression of DAT (no data has been published 
Figure 20 Effect of KN-93+AMPH Treatment of DA Transport Kinetics of DAT 615C: KN-
93+AMPH (1 µM KN-93 for 30 minutes followed by 10 µM AMPH for 30 minutes) treatment 
resulted in significant reduction in DA transport Vmax for the R615C variant. DA transport Vmax and 
Km are expressed as pmol/well/min and µM respectively. A significant decrease in the DA 
transport Vmax was observed after KN-93+AMPH treatment (65±10, basal vs. 42±3, KN-
93+AMPH; n=4, P<0.05, Studentʼs t test) without a significant change in Km (5.4±1.5, basal vs. 
3.8±0.6, KN-93+AMPH; n=4, P>0.05, Studentʼs t test).  
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as to whether DAT/flotillin-1 associations are present in recycling endosomes or 
limited to the plasma membrane), as opposed to a change in microdomain 
localization, we used confocal imaging to compare the differential localization of 
YFP-tagged DAT 615R and 615C proteins with Alexa 647-conjugated cholera 
toxin B subunit (CTxB). The latter probe detects GM1 ganglioside, a molecule 
known to localize to cholesterol-rich, membrane microdomains (Simons and 
Ikonen, 1997). In transfected N2a cells, DAT  
 
 
has been found to exhibit a significant localization to CTxB-labeled membranes, 
in contrast to the transferrin receptor (Adkins et al., 2007) which was excluded 
from these domains. As shown in Figure 22, localization of DAT 615C to CTxB-
labeled membranes was significantly reduced compared to DAT 615R.  
 
Figure 21 Flotillin-1 Association is Reduced for DAT 615C: Left: Representative western blot 
showing reduced association of DAT 615C with flotillin-1. Right: Quantification of flotillin-1 co-IP 
with DAT normalized to respective inputs. DAT 615C displays significantly reduced association 
with flotillin-1 (33±8 % of 615R; n=5, P<0.001, Studentʼs t test). 
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DAT 615C acts dominantly via generation of local negative charge to 
disrupt AMPH actions 
The ADHD subject with whom we initiated our studies is heterozygous for 
the R615C variant, suggesting that if the variant is a significant risk determinant 
for the disorder, it likely acts dominantly to alter DAT function. One mechanism 
by which dominance could be established is from an ability of the DAT R615C 
variant to preclude association of molecules needed for normal DAT trafficking 
and function, possibly as a consequence of the transporterʼs ability to dimerize 
Figure 22 Decreased Localization of DAT 615C to GM1-containing Membrane 
Microdomains: Left: HEK 293T cells were transiently transfected with YFP-HA-DAT or YFP-HA-
DAT 615C (green). Alexa 647 conjugated cholera toxin B is used to mark GM1 ganglioside (red). 
Representative cells are shown with white arrows indicating lack of DAT association with the raft 
fraction of R615C variant. Right: ICQ analysis was performed to define quantify colocalization of 
YFP-DAT with CTx-B labeled membranes. Although both 615R and 615C DAT are significantly 
colocalized with CTx-B, 615C exhibits a significantly reduced ICQ value compared to 615R 
(615R, 0.1±0.006 vs. 615C, 0.06±0.006; n=22, P<0.01, Studentʼs t test). 
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(Sorkina et al., 2003a, Torres et al., 2003). To explore this idea, we synthesized 
peptides that comprise the last C-terminal 24 amino acids of either DAT 615R or 
615C attached to the membrane permeable TAT sequence (Schwarze et al., 
1999). Incubation of DAT 615R cells with the TAT-C24615R peptide failed to 
impact AMPH-mediated downregulation of DA uptake (Figure 23A).  However, 
incubations of these cells with the TAT-C24615C peptide eliminated the effects of 
AMPH on the wildtype transporter (Figure 23A). Addition of either TAT-C24 615R 
or TAT-C24615C peptide (or no peptide) produced no effects on either basal or 
AMPH-modulated DA transport of DAT 615C cells (Figure 23B). These findings 
suggest that rather than attracting molecules that can drive DAT 615C out of 
GM1 and flotillin-1 containing membrane microdomains, the 615C-substituted C-
terminus may preclude interactions needed for successful residency in these 
compartments. 
Next I sought to determine whether the 615C substitution per se perturbs 
DAT regulation, or whether the loss of Arg residue at this position confers AMPH 
insensitivity.  Following site-directed mutagenesis of the wildtype DAT C-terminus 
at residue 615, we found that cells transfected with DAT 615A presented a 
pattern of AMPH regulation indistinguishable from those of DAT 615R (Figure 
24), indicating that Cys addition, rather than Arg loss, determines AMPH 
insensitivity. Cytoplasmic Cys residues can be modified by palmitoylation or 
nitrosylation (Nagahara et al., 2009), modifications that have both been 
	   87	  
suggested to occur with catecholamine transporters (Kaye et al., 2000, Foster 
and Vaughan, 2011). 
 However, we detected no differences in palmitoylation between wildtype 
DAT and the R615C variant, and NOS inhibition did not restore AMPH regulation 
(data shown in appendix). Cys residues also participate in disulphide bond 
formation, though this seems unlikely given the reducing environment of the 
cytosol where the DAT C-terminus resides. Cytoplasmic Cys residues can form 
acidic thiolates (Nagahara et al., 2009) and as such could confer a charge 
inversion compared to the wildtype 615R residue. Therefore, we asked whether 
Figure 23 Effect of TAT-C24615R and TAT-C24615C peptides on AMPH-mediated DA 
Transport Reduction: (A, B) Exogenous addition of TAT-C24615C peptide blocks AMPH-
mediated reduction in the DA transport for DAT 615R and had no effect on 615C. Addition of 
either TAT-C24615R or TAT-C24615C peptide (10 µM, 18hrs) did not alter basal DA uptake 
compared to no peptide control for both DAT 615R and 615C (for DAT 615R, 104±6% with TAT-
C24615R and 102±3% with TAT-C24615C; for DAT 615C, 96±3% with TAT-C24615R and 103±4% 
with TAT-C24615C). Addition of TAT-C24615R peptide or no peptide control produced a significant 
reduction in DA uptake for DAT 615R upon AMPH (10 µM, 30 min) treatment (72±6% of basal no 
peptide for TAT-C24615R and 77±5% of basal no peptide for TAT-C24615C) and had minimal effect 
on DAT 615C (84±2% of basal no peptide for TAT-C24615R and 85±1% of basal no peptide for 
TAT-C24615C). Addition of AMPH (10 µM, 30 minutes) to TAT-C24R615C peptide treated DAT 615C 
cells also did not produce a significant reduction in DA uptake (88±4% basal no peptide control). 
AMPH addition to TAT-C24615C treated WT-DAT cells significantly blocked AMPH-mediated 
reduction in the DA transport seen in TAT-C24615R treated and no peptide control conditions 
(91±3% basal no peptide control). Significant differences were calculated using Studentʼs t-test. 
(n=3-4, P<0.05). 
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DAT 615E would also confer insensitivity to AMPH. Indeed, DAT 615E displayed 
no reductions in DA uptake in response to AMPH treatment (Figure 24). Since 
the mutants 615K, 615A, 615Q, and 615S all respond to AMPH (Figure 24), we 
suggest that a negative thiolate arising from Cys substitution at the 615 position 
is responsible for the shift of the DAT R615C variant to AMPH insensitivity. 
 
  
The Arg residue at 615 of DAT forms a canonical phosphorylation site for multiple 
kinases with Thr 613 (Amanchy et al., 2007). However, since the 615A 
substitution is still AMPH-sensitive, phosphorylation at 613T is not required for 
the psychostimulantʼs impact on DAT regulation. Consistent with this finding, 
cells transfected with the T613A mutant retained AMPH sensitivity (Figure 25). 
However, cells transfected with a T613E mutant on the wildtype 615R 
Figure 24 Effect of Amino Acid Substitutions at R615 residue on AMPH-mediated DA 
Transport Reduction: Presence of DAT 615C or a negatively charged aspartic acid (613E) 
blocked AMPH-mediated reduction in the DA transport. Specific DA uptake values are expressed 
as % of basal control. Only DAT 615C (103±13% of basal) and 615E (102±12% of basal) 
mutations did not display reduction in the DA uptake upon AMPH-treatment (10µM, 30 min). All 
other mutations at R615 position and DAT 615R showed a significantly reduced DA uptake upon 
AMPH treatment (615R-68±3%, 615K-75±6%, 615A-66±5%, 615Q-78±5%, 615S-73±5% of 
basal). Significant differences were calculated using Studentʼs t-test for each mutation. (n=3-4, 
P<0.05). 
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background to mimic the charge that would be induced by Thr613 
phosphorylation lost AMPH sensitivity (Figure 25). These findings suggest that 
Thr613 may need to remain dephosphorylated to sustain psychostimulant (and 
PKC) regulation and that a nearby 615C thiol/thiolate may sufficiently mimic the 
structure or negative charge of phosphorylated Thr613 to preclude DAT 
regulation by AMPH. 
 
Discussion 
DAT proteins have been found to reside within cholesterol and GM1 
ganglioside-enriched membrane microdomains, often referred to as “lipid” or 
“membrane rafts” (Sandvig and van Deurs, 2000, Adkins et al., 2007, Foster et 
al., 2008), and to associate with the raft-associated protein flotillin-1 (Cremona et 
al., 2011). Adkin and coworkers demonstrates that DAT proteins that are 
Figure 25 Importance of T613 Residue in AMPH-mediated DA Transport Reduction: 
Introduction of a negative charge by T613E mutation abolishes AMPH-mediated reduction in the 
DA transport. AMPH treatment (10 µM, 30 minutes) caused a significant reduction in the DA 
transport for DAT 615R and 613A (DAT 615R-77±5%, 613A-81±3% of basal) T613E mutation 
completely blocked AMPH-mediated reduction in the DA transport (97±4% of basal). Mutation of 
T613 to either A or E on DAT 615C background and 615C alone eliminated reductions in DA 
uptake upon AMPH treatment (10 µM, 30 minutes) (DAT 615C-92±5%, 613A-615C-86±3%, 
613E-615C-92±4% of basal). Significant differences were calculated using Studentʼs t-test for 
each mutation. (n=5, P<0.01) 
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localized to CTxB-labeled membrane microdomains demonstrate restricted 
mobility but can be mobilized by membrane cholesterol extraction (Adkins et al., 
2007). We found a reduced colocalization of DAT 615C with CTxB-labeled 
membranes, as well as a reduced association of the membrane raft-associated 
protein flotillin-1. Since quantitation of our co-immunoprecipitation data was 
normalized for total DAT protein, the reduced flotillin-1 association of the R615C 
variant may reflect, at least in part, the reduced surface expression of the 
transporter. However, at present we do not know whether DAT and flotillin-1 have 
constitutive or dynamic interactions during normal transporter recycling. In the 
context of our immunofluorescence findings of a surface redistribution of R615C 
between GM1+ and GM1- compartments, we should also consider DAT targeting 
to a compartment where opportunities for flotillin-1 interactions are lost versus a 
direct effect on flotillin-1 associations is involved.  
Cremona et al. (2011) provided evidence that interactions with flotillin-1 
are required for both PKC-dependent DAT trafficking and AMPH-induced DA 
efflux. Consistent with these findings, we observed a loss of PKC-induced 
transporter trafficking with DAT 615C, though AMPH-induced DA efflux was 
maintained. These findings indicate that DAT/flotillin-1 associations support, but 
may not be necessary, for AMPH-triggered DA efflux. Since CaMKII associates 
with DAT through C-terminal sequences that overlay the R615 residue and is 
critical for AMPH-triggered DA efflux (Fog et al., 2006), the constitutively elevated 
DAT/CaMKII association may compensate for the loss of flotillin-1 associations, 
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hyperphosphorylating DAT under basal conditions and thereby enhancing the 
efflux-competence of DAT 615C. Alternatively, since DAT responds rapidly to 
AMPH action via increased surface expression (Furman et al., 2009a), the 615C 
substitution may also enhance DAT levels transiently in response to AMPH, 
during the period of DA efflux measurements. Regardless, these findings raise 
the possibility that flotillin-1 and CaMKII interactions may be exclusive, with their 
exchange being a key feature of dynamic DAT regulation. Recently, a Ras-like 
GTPase, Rin, was shown to associate with DAT C-terminus in membrane rafts 
and regulate PKC-mediated DAT downregulation (Navaroli et al., 2011). The 
mislocalization and regulatory perturbations we observe with DAT 615C could 
therefore be derived from altered Rin associations, an issue that deserves further 
study.   
As we further explored the role of CaMKII in the insensitivity of the R615C 
variant to AMPH-induced internalization, we discovered a capacity for the kinase 
to support a trafficking-independent mode of transporter functional regulation. We 
hypothesize that CaMKII activity maintains basal activity of DAT 615C when 
transporters are localized away from flotillin-1 rich membrane microdomains. 
Although we did not obtain evidence for this process in DAT 615R cells, CaMKII 
associations may provide a mechanism whereby more physiological stimuli could 
enhance DAT activity, possibly during states of high DA release. In this regard, 
both NET and SERT proteins exhibit trafficking-independent catalytic regulation 
(Apparsundaram et al., 2001, Steiner et al., 2008). Moreover, a future study with 
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the DAT V382A variant, which also exhibits trafficking independent DAT 
modulation after PKC activation, should evaluate membrane microdomain 
associations to address this conundrum. 
Studies examining the physical requirements for AMPH regulation of 
wildtype DAT in relation to the R615C variant provide key insights into 
mechanisms supporting transporter regulation. Using TAT-C24615R and TAT-
C24615C peptides, we demonstrated that the mutant C-terminus acts dominantly 
to eliminate AMPH actions on wildtype DAT. These findings are important given 
the hemizygous status of our DAT 615C proband. These findings also indicate 
that DAT 615C may compete in the hemizygous state with the wild-type DAT C-
terminus for key interactions needed for AMPH-induced transporter regulation.  
Additionally, we found that whereas 615C precludes AMPH-induced transporter 
downregulation, Ala, Lys, Gln, and Ser substitutions at R615 fail to perturb 
regulation. In further pursuit of the structural basis for the 615C effect, we found 
that 615E recapitulated the impact of 615C, suggesting that the generation of 
negative charge in the distal C-terminus may play a role in disrupting transporter 
regulation. Cys residues can exist as thiolates and thereby create a local 
negative charge (Nagahara et al., 2009). Whereas the pKa of a free Cys thiol is 
estimated at ~8, leaving the Cys side chain of 615C largely protonated, the pKa 
of proteinaceous Cys residues is known to be quite sensitive to its local 
environment, where the thiolate anion can be stabilized by surrounding residues 
(Netto et al., 2007).  
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Since R615 forms a potential phosphorylation site that includes T613, we 
considered the possibility that 615C gains its capacity to disrupt regulation by 
interfering with T613 phosphorylation. However, we found that a 613E mutation, 
created to produce the negative charge associated with Thr phosphorylation, like 
615C eliminates DAT responsivity to AMPH. These findings suggest that 
dephosphorylation of T613 may be a critical step in sorting DAT into regulated 
versus constitutive endocytic pathways.  Further studies are needed to determine 
whether, and under what conditions, kinases and phosphatases may target this 
residue, either constitutively or as part of a rapid, regulatory mechanism, or 
whether other mechanisms, such as charge-dependent protein associations, 
impart sorting decisions. 
In toto, our findings lead us to propose a two-compartment model for the 
functional impact of DAT 615C (Figure 26), one that also has implications for the 
regulation of DAT 615R. We propose that DAT exists at the cell surface in 
GM1/flotillin-1 enriched microdomains that restrict transporter lateral mobility and 
access to key endocytic proteins that provide for regulated trafficking. 
Additionally, the transporter may reside in membrane depleted of these raft 
components and, if so, traffics largely via constitutive endocytosis and rapid 
recycling. Decisions dictating the localization and trafficking of DAT are 
dependent on sequences in the distal C-terminus of DAT, which we suspect 
involves phosphorylation/dephosphorylation reactions at T613. With the DAT 
615C substitution, transporters are biased to traffic into and recycle from GM1- 
	   94	  
and flotillin-1 depleted microdomains, leading to constitutive trafficking at higher 
rates than seen for transporters in GM-1 and flotillin-enriched microdomains. 
 Our model has parallels with the differential trafficking of insulin-
responsive (GLUT4) and nonresponsive (GLUT1) glucose transporters. GLUT4 
and GLUT1 equivalently support glucose uptake, but GLUT4 traffics through a 
limited capacity, regulated pathway whereas, GLUT1, traffics in the same cells 
through higher-capacity, constitutive mechanisms (Zorzano et al., 1997).  
Wildtype DAT has the capacity to occupy either a regulated or constitutive 
Figure 26 Model Describing Differential Trafficking of DAT 615R and DAT 615C to the 
Regulated and Constitutive Endocytic Pathways and Biased Localization Toward 
GM1/flotillin-1 rich or Depleted Membrane Microdomains: DAT molecules are depicted as 
located in trafficking vesicles or at the plasma membrane as homomeric or heteromeric dimers 
(though other configurations are acceptable). Transporters localize to two types of membrane 
domains, one domain enriched for GM1 ganglioside and flotillin-1, with the other domain relatively 
depleted of these molecules. Homo-multimers of WT DAT (615R) subunits target preferentially to 
GM1 ganglioside/flotillin-1 enriched compartment as compared to DAT 615C subunit containing 
dimers. The heterodimer is shown preferentially targeting domains that are depleted of GM1 and 
flotillin-1, in keeping with the dominant action of the 615C mutation in the ADHD proband and the 
dominant action of the DAT C-terminal peptide containing 615C. DAT 615C subunits are 
diminished in surface levels relative to WT subunits. Microdomains enriched for GM1 and flotillin-
1 support regulated trafficking of DATs, and under basal conditions exhibit slow rates of 
endocytosis, whereas membranes depleted of GM-1 and flottilin-1 support more rapid, 
constitutive endocytosis and recycling. 
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pathway, but in our model systems is biased normally toward GM1/flotillin-1 
enriched domains. As shown by our studies with the DAT615C peptide, the DAT-C 
terminus can play a dominant role in the transporterʼs capacity to enter a 
regulated trafficking pathway. The DNA encoding DAT 615C and the other 
mutants generated in this study, as well as the DAT615C peptide should be useful 
in further elucidating the mechanisms by which DAT sorts between surface 
trafficking pathways. Although the 615C variant is rare, our findings suggest that 
a more intensive analysis of proteins that sustain DAT membrane 
compartmentalization and recycling kinetics may provide important insights for 
idiopathic ADHD.     
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CHAPTER V 
 




In Chapter I, I introduced the DAT A559V variant and here I summarize 
briefly its properties so that the reader may be reminded of key aspects of the 
variantʼs biology, leading to my contributions. The A559V variant was initially 
identified in a female bipolar disorder subject (Grunhage et al., 2000), but further 
analyses were not pursued. The lack of effort to characterize the variant was 
likely due to the limited pedigree from which it was derived, and the fact that 
transmission could not be verified as the parent likely transmitting the variant was 
deceased. However, it must be said that the rarity of the variant also likely 
factored into this decision as the investigators pursuing this effort were searching 
for more common contributions to bipolar disorder.  In 2005, our lab identified a 
second occurrence of DAT A559V in two male siblings with ADHD (Mazei-
Robison et al., 2005). The pedigree of the A559V cohort is shown in Figure 27. 
All members of the pedigree that possess the A559V variant are hemizygous for 
this substitution, though they are homozygous for a noncoding 3ʼUTR variant that 
has been associated with ADHD (Mazei-Robinson and Blakely, 2006). The 
A559V variant is located in TMD 12, whose function remains largely unknown, 
though crystallographic studies of a bacterial homolog (Yamashita et al., 2005), 
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and structure function studies of SERT (Just et al., 2004) suggest that TM12 
contributes to a homo-oligomeric interface. In the latter case, it is reasonable to 
speculate that a dominant-negative action of the mutant transporter could arise 
through perturbation of oligomerization. Such an action would help explain a 
contribution to ADHD (or bipolar) risk in subjects who are hemizygous for the 
variant. 
  
Our previous report indicates that the anomalous DA efflux (ADE) that is 
detected in the A559V variant under basal conditions increases in a voltage-
dependent manner when monitored in voltage-clamped, transfected HEK-293T 
cells. Remarkably, basal ADE was completely blocked by AMPH, whereas AMPH 
produces DA efflux from cells expressing WT DAT. As I reviewed earlier in this 
thesis, evidence indicates that AMPH-mediated DA efflux is regulated by CaMKII-
dependent phosphorylation of the DAT N-terminus phosphorylation (Fog et al., 
Figure 27 Pedigree of the A559V Variant: Siblings with ADHD are indicated by black boxes and 
were both hemizygous for the A559V variant. Transmission of the allele occurred from the mother 
and grandmother. Family members who did not suffer from ADHD are shown in gray. Open 
symbols indicate that these family members were not evaluated for ADHD symptoms (Mazei-
Robison et al., 2005). 
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2006). My studies with the A559V variant specifically address the following three 
questions:  
1) Is ADE of the A559V variant associated with increased basal 
phosphorylation?  
2) Are the expected AMPH-mediated DA transport reductions and net DAT 
surface internalization observed in A559V-transfected cells, similar to my 
prior findings with the DAT 615C variant? 
3) Are any changes in AMPH actions on A559V-transfected cells also 
observed with β-PMA treatments? 
The ADE exhibited by the A559V variant was observed in transiently 
transfected HEK 293T cells. To explore whether changes in basal 
phosphorylation arise under the same conditions, I employ the same expression 
methods as used for ADE measurements. To investigate AMPH- and β-PMA-
mediated regulation, I utilize WT and DAT A559V stable lines produced with Flp-
In™ HEK cells that provide for equivalent, stable expression from the same 
genomic locus.  
 
Results  
To explore whether ADE from the DAT A559V variant is accompanied by 
increased transporter phosphorylation, we utilized [32P]orthophosphoric acid 
metabolic labeling of transiently transfected HEK-293T cells, followed by 
immunoprecipitation with a DAT-specific antibody. Immunoprecipitated DATs 
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were resolved by SDS-PAGE and phosphorylation was detected by exposure of 
gel transfers to X-ray film. I found that the A559V variant displayed a significant 
increase in basal phosphorylation compared to WT DAT or from non-transfected 
cells (Figure 28). Similar results were obtained by the Javitch lab using site-
specific phosphor-antibodies, which indicated that A559V expressing cells 
display a significant increased phosphorylation at Ser 7 and Ser 13 residues and 
a trend towards increased basal phosphorylation at Ser12 (Bowton et al., 2010). 
In parallel with these studies, the Galli lab (Bowton et al., 2010) demonstrated 
that ADE from the A559V variant was dependent on D2S receptor activity and 
dependent on sites likely to mediate CaMKII-mediated DAT phosphorylation. 
 
In the Blakely labʼs initial report that described the ADE phenotype of the 
A559V variant, they showed that ADE could surprisingly be blocked by AMPH 
treatment whereas AMPH caused DA efflux from WT DAT expressing cells. 
Figure 28 Increased basal phosphorylation of the A559V variant: Top: Representative 
autoradiograph from immunoprecipitations of [32P] PO4 labeled cells. Bottom: Quantification of 
DAT bands from the autoradiograph showing significant increase in basal phosphorylation levels 
of A559V (275±42 % of WT; n=4, P<0.001, One-way ANOVA followed by Bonferroniʼs post hoc 
test.). Data represent protein labeling normalized by protein loading.  
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These finding lead me to investigate the actions of AMPH on DAT A559V activity 
and surface expression. Although transiently transfected HEK 293T cells offer an 
excellent, single cell readout of basal DA leak, population-based assays such as 
those monitoring DA transport or cell surface biotinylation benefit stably-
transfected cells. Conventional stable cell methods utilize genes or cDNAs 
randomly integrated into host cells. Clonal lines derived from these methods 
often produce different levels of expression due to different sites of integration 
and a lack of control over the copy number of genes integrated.  To minimize 
these issues, we used Flp-In™ HEK cells to produce stable WT DAT and DAT 
A559V cells as these cells provide for single copy expression from the same 
genomic locus.  
 
As mentioned previously, AMPH normally causes a reduction in DA 
transport activity and a loss of transporters from the cell surface via clathrin-































Figure 29 Effect of AMPH on DA Transport Reduction: AMPH-mediated (10 µM, 30 minutes) 
reduction in DA transport seen in WT DAT (66±5 % of basal) whereas no significant changes 
were detected for A559V cells (89±5 % of basal). Basal DA transport levels were normalized to 
uptake in cells treated with vehicle. Significant differences were calculated using Studentʼs t-test. 
(n=4, P<0.001) 
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as noted in a prior chapter, our stable cells that express WT DAT displayed a 
significant reduction in DA transport upon a 30 min, 10 µM AMPH treatment. In 
contrast, DAT A559V variant expressing cells failed to exhibit a reduction in DA 
transport (Figure 29). Loss of DA transport, as previously documented, was 
found to be paralleled by a net reduction in surface expression of WT DAT. As 
with the insensitivity of DAT A559V-mediated DA transport to AMPH, the variant 
displayed no AMPH-induced reduction in surface expression (Figure 30). These 
findings were replicated in transiently transfected HEK 293T cells (E. Bowton, 
unpublished data).  
 Previous studies conducted in transiently transfected COS-7 and SH-SY-
5Y cells that assessed the impact of PKC activation on DA transport by WT DAT 
and the DAT A559V variant indicated no significant differences (Mazei-Robison 
and Blakely, 2005). The lack of AMPH regulation of DAT A559V regulation in the 
Figure 30 Effect of AMPH on DAT Surface Expression: Left: Representative western blot 
showing surface DAT protein levels after AMPH treatment (10 µM, 30 minutes) for WT DAT and 
DAT A559V transfected cells. Total β-actin is used as an intracellular loading control. Right: 
Quantification of AMPH-induced decrease in DAT surface levels expressed as surface/total. Data 
is normalized to basal DAT surface/total expressions as 100%. AMPH treatment caused a 
significant (63±7%) decrease in wt DAT expression while no change was detected in A559V 
expression (92±3%). Significant differences were calculated using one-way ANOVA followed by 
Bonferroniʼs post hoc test. (n=6, P<0.0001) 
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Flp-In HEK stable cell lines prompted me to verify these observations in this cell 
background. Consistent with the transiently transfected model studies, β-PMA 
induced a significant reduction in DA transport by both WT DAT and DAT A559V 
stable cells (Figure 31). β-PMA treatments also produced a significant loss of 
surface expression for both WT DAT and DAT A559V cells (Figure 32). 
Therefore, the lack of transport and trafficking sensitivity to AMPH possessed by 
the A559V variant, unlike findings with the R615C variant, does not translate to 
activated PKC-triggered DAT regulation. 
Recently it was shown that AMPH-induced DA efflux was dependent on 
DAT/flotillin-1 interaction (Cremona et al., 2011). Following the analogy, one can 
speculate that ADE must be occurring from flotillin-1 rich membrane 



























Figure 31 Effect of β-PMA on DA Transport Reduction: β-PMA-mediated (200 nM, 30 
minutes) reduction in the DA transport seen in both WT DAT and the A559V variant. Basal DA 
transport levels were normalized to respective cell lines and β-PMA-mediated reduction was 
calculated. β-PMA caused a significant decrease in DA transport of WT DAT (63±5 % of Veh) as 
well as in the A559V variant (71±6 % of veh). Significant differences were calculated using 
Studentʼs t-test. (n=3, P<0.001) 
	   103	  
conditions, a hypothesis, that still remains to be investigated. However, when the 
colocalization of the A559V variant with ganglioside GM1 was measured, a 
significant difference in the colocalization ICQ of DAT-WT/GM1 and DAT-
A559V/GM1 was not observed (Figure 33).  Flotilin-1 and GM1 colocalize in 
membrane microdomains, often referred to as lipid rafts. This finding itself is very 
interesting as it points to the possibility of differential targeting of transporters to 
specialized membrane microdomains and heterogeneity of cell membrane. 
Further studies are required to address this question. 
 
Discussion 
 DAT dictates the duration and magnitude of DA signaling by removing the 
catecholamine from the synapse and thereby terminating DA actions on pre- and 
Figure 
 
 32 Effect of β-PMA on DAT Surface Expression: Left: Representative western blot showing 
surface DAT protein levels after β-PMA treatment (200 nM, 30 minutes) for both WT and A559V 
DAT. Total β-actin was used as an additional loading control. Right: Quantification of β-PMA-
induced decrease in DAT surface levels expressed as surface/total. Data is normalized to basal 
DAT surface/total expressions as 100%. β-PMA treatment caused a significant decrease in both 
WT DAT (72±5 % of Veh) and DAT A559V (60±0.4 % of Veh) expression. Significant differences 
were calculated using Studentʼs t-test. (n=3, P<0.0001) 	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postsynaptic DA receptors. The psychostimulant AMPH alters DAT activity by 
modulating DAT function and surface expression (Saunders et al., 2000). AMPH, 
being a weak base substrate of VMAT1 and 2, is known to deplete the synaptic 
vesicles of DA and, with activation of CaMKII, produces DAT-dependent DA 
efflux in vitro and in vivo (Sulzer et al., 2005). In addition to producing non-
vesicular DA release, AMPH also has CaMKII-dependent effects on the surface 
expression of DAT, triggering net relocation of DAT to intracellular compartments 
(Wei et al., 2007b).  
Our previous report demonstrated a novel A559V-associated ADE that 
could be blocked by both AMPH and MPH, two drugs used to treat ADHD. The   
similarity here between the actions of AMPH and methylphenidate were 
unexpected given that 1) AMPH causes, not blocks, DA efflux with WT DAT and 
2) AMPH and methylphenidate act in opposition with WT DAT, one a substrate 
Figure 33 Colocalization of DAT with Ganglioside GM1: Left: HEK 293T cells are transiently 
transfected with YFP-HA-DATs (green). Alexa 647 conjugated cholera toxin B (CTxB) is used to 
mark GM1 ganglioside (red). Representative cells are shown with yellow merge indicating DAT 
association with the raft fraction. Right: ICQ analysis is performed to define colocalization of 
YFP-DAT with CTx-B labeled lipid rafts. Quantification demonstrated that both WT and A559V 
DAT are significantly colocalized with CTx-B. The differences between colocalization ICQ are not 
significantly different. (DAT-WT, 0.1±0.006 vs. DAT-A559V, 0.08±0.01; n=22, P>0.05, Studentʼs t 
test).  
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and the other an antagonist that can actually block the actions of the other. Since 
both compounds now act in a similar manner in vitro, as they do therapeutically in 
vivo, the occurrence of an enhanced leak state needs to be considered more 
broadly than just a feature of the A559V variant. 
As noted above, AMPH-induced DA efflux is dependent on CaMKII-
activation and appears to involve DAT phosphorylation (Fog et al., 2006). Thus, 
basal DA leak could be a result of increased basal DAT phosphorylation. When 
we assessed basal levels of phosphorylation of the A559V variant, we found it to 
be true confirming the former hypothesis. Moreover, PKC activation is also linked 
to DA efflux (Kantor and Gnegy, 1998, Johnson et al., 2005b) and PKC-mediated 
DAT internalization has been reported to occur through lipid raft microdomains 
(Cremona et al., 2011). A normal response of DAT A559V variant to PKC 
activation as well as WT like association with lipid raft component, GM1, 
suggests that A559V-associated ADE is likely to be a consequence of changes 
arising from within lipid rafts, rather than the altered domain localization seen with 
DAT 615C.  
 To explore further the effects of AMPH on the A559V variant, we 
developed stable lines using Flp-In HEK cells to capture the opportunity to have a 
homogenous population of cells expressing either WT DAT or DAT A559V from 
the same genomic locus. Here, we showed that the A559V variant lacks the 
ability to internalize following AMPH treatment. This property was not due to a 
global loss of the A559V regulation, as PKC activation lead to a reduction in DA 
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transport, as well as a loss of the A559V variant from the cell surface similar to 
WT DAT. Since AMPH acts as an antagonist at DAT A599V in the ADE 
paradigm, it is possible that AMPH is not transported inside the cell (although it 
readily transports DA) and therefore cannot activate signaling pathways required 
for transporter internalization. Previous studies have shown that intracellular 
injection of AMPH was sufficient to cause trafficking from an uptake-impaired 
Y335A DAT mutant (Kahlig et al., 2006). Alternatively, DAT A559V, in assuming 
a conformation that produces ADE, may have entered a state that cannot receive 
intracellular signals that produce DAT endocytosis. Additional studies with DAT 
A559V that assess 1) AMPH internalization, 2) impact of injected intracellular 
AMPH on transporter trafficking, 3) changes in transporter conformations, as with 
Cys modifying reagents, and 4) altered protein associations may be able to select 
among these possibilities. 
Although, like DAT 615C, the DAT A559V variant is rare. Nonetheless, 
studies of the mutant may more broadly inform how ADE contributes to ADHD as 
well as defining the exact mechanisms by which AMPH and methylphenidate 
effectively treat ADHD. Additionally, study of rare coding variants such as DAT 
A559V can help us define a broader network of genes that regulate DA 
neurotransmission and help search for additional determinants of risk for ADHD 
and its comorbid disorders. An important step in this direction is the generation 
and characterization of DAT A559V knock-in mice, currently underway in the 
Blakely lab. 





SUMMARY AND FUTURE DIRECTIONS 
 
DA signaling is of critical importance in multiple behaviors including motor 
control, reward, working memory, and mood. Dopaminergic dysfunction has been 
linked to many neuropsychiatric disorders including addiction and schizophrenia, 
as well as to the movement disorders dystonia and Parkinsonʼs disease. An 
important player in maintaining DA tone in the brain is DAT. DAT knock-out mice 
display tonically-elevated extracellular DA levels, reduced presynaptic DA stores 
and extreme hyperactivity. In contrast to the mouse findings, which could suggest 
a link between altered DAT and ADHD, human subjects with IPD were found to 
possess a full genetic loss of DAT function (Kurian et al., 2009). Thus, prior to the 
Blakely labʼs efforts to further pursue DAT in ADHD, neuropsychiatric disorders 
directly linked to DAT dysfunction were unknown. Possibly, functional 
compensations in vivo could mask the phenotype of low penetrance DAT 
dysfunction, or simply that a correct clinical phenotype had yet to be identified.  
 In large part, the fact that DAT is the site of action for the most commonly 
prescribed ADHD medications, the Blakely lab pursued ADHD as a disorder 
enriched in penetrant gene variants. Since DAT coding exons had already been 
screened for variants in a large number of subjects (Grunhage et al., 2000, 
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Vandenbergh et al., 2000), it was clear that common coding polymorphisms were 
unlikely to exist that would implicate structural changes in the transporter for 
population ADHD risk. Nonetheless, the identification of highly penetrant, rare 
DAT coding variants could help solidify the case for DA dysfunction in ADHD, 
much as the occurrence of rare mutations in genes linked to protein ubiquitination 
in Parkinsonʼs disease have opened new opportunities for progress in this 
disorder. Parallels to this position can also be made with the goal of forward 
genetic studies, where the identification of single mutant alleles can lead to the 
identification of undiscovered pathways that underlie broader phenotypes as well 
as disease states (e.g. the discovery of ced-1 (Horvitz, 2003) and signaling 
leading to apoptosis in C. elegans). 
 Using a high-throughput, polymorphism discovery approach our lab has 
identified four nonsynonymous (or coding), single nucleotide polymorphisms 
(SNPs) in the DAT gene (SLC6A3). These four variants (V24M, L167F, A559V, 
and R615C) are distributed throughout the transporter sequence and are present 
on intracellular as well as extracellular sides and in a transmembrane domain 
(Figure 34). The first of these variants to be identified, and a subject of study in 
this thesis is A559V. The fact that the A559V variant was originally identified in a 
bipolar disorder subject (Grunhage et al., 2000), and then was rediscovered in 
two siblings with ADHD (Mazei-Robison et al., 2005), a disorder comorbid with 
bipolar disorder, seems unlikely to be a chance finding. In this regard, children of 
subjects with bipolar disorder are three times more likely to have ADHD 
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compared to children of unaffected subjects (Faraone and Tsuang, 2003). 
Likewise, subjects with an ADHD diagnosis are more likely to have a relative with 
bipolar disorder than non-ADHD subjects (Kunwar et al., 2007).  
 
 The allele encoding the A559V mutation is present in single copy in all 
carriers in the pedigree within which it was found, and was transmitted to the two 
affected boys from the mother and the maternal grandmother. Unfortunately, 
given the male:female bias of ~4:1 in ADHD, no other male relatives could be 
identified as carriers of the variant. The two female carriers did not possess 
symptoms that qualify for an ADHD diagnosis, though the mother reported a mild 
Figure 34 Localization of ADHD-associated DAT Coding Variants: Schematic Topology of 
DAT Based on LeuTaA crystal structure is depicted. TMDs1-5 and 6-10 form inverted 
triangle configuration and fold over forming substrate translocation pathway. TMDs 11 
and 12 stick out from other TMDs, possibly contributing to the oligomerization. Adapted 
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learning disability, and the grandmother scored above the 95th percentile for 
impulsivity traits on the Connorʼs instrument (Mazei-Robison et al., 2008).   
 Under basal conditions, the DAT A559V variant displays anomalous DA 
efflux (ADE) that can be blocked by methylphenidate, cocaine and AMPH (Mazei-
Robison et al., 2008). More recently, ADE has been found to be supported by 
tonic signaling of DA D2 receptors that are expressed on the same cells and that 
act via a CaMKII-mediated mechanism (Bowton et al., 2010). CaMKII is 
suspected to phosphorylate DAT at N-terminal Ser residues known to be required 
for AMPH-induced DA efflux (Khoshbouei et al., 2004, Fog et al., 2006). In this 
thesis, I presented evidence demonstrating that DAT A559V is 
hyperphosphorylated relative to WT DAT, suggesting that the mutation may 
trigger ADE by permitting the transporter to achieve conformations like those 
seen following AMPH treatments. Since, at the present, DAT A559V is not known 
to have a cell-autonomous action in elevating intracellular Ca2+ levels and in 
activating CaMKII, we cannot conclude that this conformation permits the 
phosphorylation of the DAT N-terminus by CaMKII. Indeed, unpublished data 
from the Galli lab (Bowton et al., manuscript in preparation) links the PKCβ 
signaling to the ADE associated with the A559V variant. Thus, treatment of cells 
with a PKCβ-specific inhibitor eliminates the ADE of the A559V variant and 
rescues the ability of AMPH to produce nonvesicular DA release. Comparable 
studies involving kinase inhibitors, in the context of [32P] orthophosphoric acid 
metabolic labeling studies, will be important in further clarifying this mechanism. 
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Studies are also currently underway in the Blakely lab to identify the 
phosphorylation sites responsible for the hyperphosphorylation of DAT A559V. 
 Due to the evidence of a functional perturbation of the A559V variant with 
in vitro studies, the Blakely lab recently generated a DAT A559V knock-in mouse 
line using transgenic technology (Mergy, 2011). Biochemical and behavioral 
analyses of these mice are in progress, though preliminary findings demonstrate 
a novel darting (hyperactive) phenotype, as well as blunted DA release from 
striatal slices in vitro, and a reduced locomotor response to AMPH in vivo. 
Studies are also needed that investigate signaling network alterations, 
particularly those mediated by CaMKII- and PKCβ, with respect to DAT regulation 
in this model. Using microdialysis and chronoamperometry approaches in vivo, 
basal extracellular DA levels and DAT-mediated DA clearance should be 
explored. Finally, compensatory changes in DA target genes (e.g. DA receptors) 
and signaling proteins should be determined as evidence of alterations here may 
open opportunities for evaluation of other potential determinants of ADHD risk. 
 On a more cellular level, TMD 12 that has been suggested to contribute to 
SERT oligomerization (Just et al., 2004), and as such it will be interesting to 
monitor changes in DAT homomeric protein associations, for example using 
differentially tagged transporters or FRET-based imaging approaches. As AMPH-
induced DA efflux is known to be dependent on CaMKII and flotillin-1 association 
(Fog et al., 2006, Cremona et al., 2011), I performed a preliminary analysis of 
CaMKII/DAT associations, using WT DAT or the A559V variant, but failed to 
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detect differences (data not shown). It would be wise, however, to pursue this 
effort further in the DAT A559V transgenic mice as a more native environment 
may provide clearer evidence of a role for such associations (or not).  
 Flotillin-1 is a constituent of lipid raft microdomains that have been shown 
to harbor DAT (Cremona et al., 2011). Although I did not search for direct 
evidence of altered A559V/flotillin-1 interactions, I did investigate the 
colocalization A559V and GM1, another marker of lipid rafts. Although there was 
a slight (~20%) reduction in ICQ estimates of colocalization, this difference did 
not reach significance. The heterologous nature of these studies needs to be 
kept in mind. Further evaluation of DAT A559V/flotillin-1 interactions in 
dopaminergic nerve terminals ex vivo is now feasible with the generation of DAT 
A559V mice.  
 The central focus of this thesis is the second DAT coding variant that the 
Blakely lab identified, R615C. This variant lies in the distal C-terminus and is 
located in a well-conserved region of the transporter. The 615C variant was 
discovered in an Irish subject who displayed high scores for a diagnosis of 
combined type ADHD. The subject inherited the mutation from his mother who 
probably had ADHD as a child, based on a retrospective analysis. The subject is 
being well treated with methylphenidate. The DAT C-terminus harbors many 
domains known to support protein-protein interaction, and has been implicated in 
both constitutive and PKC-mediated, DAT regulation. The R615C variant lies 
within the RHW motif that has been reported to be involved in DAT export from 
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the ER as well as for DAT/CaMKII interaction (Bjerggaard et al., 2004, Fog et al., 
2006).  
 Studies presented in this thesis demonstrate that the DAT 615C variant 
exhibits reduced total and surface expression, which results in a significantly 
decreased DA transport Vmax but no change in DA transport KM. The fact that 
DAT 615C surface levels are reduced more than total levels was the first 
indication that a trafficking alteration may be present. The lack of an impact of the 
DAT 615C variant on the DA transport KM also supports basal trafficking or 
altered regulation as a primary contributor to any functional deficits that may be 
observed in vivo.  
 Although basal and AMPH-induced DA efflux of DAT 615C appeared 
normal, these findings, in the context of a reduced surface expression do raise 
the possibility that the variant does impact conformations of the transporter 
dictating inward versus outward substrate flux. Studies should be performed that 
evaluate DA efflux at a single cell DA efflux and normalize findings with surface 
DAT protein levels in the same cells (perhaps via DAT transient currents that are 
often used as a surrogate for surface expression). 
 As shown earlier, the DAT 615C variant lacks AMPH- and PKC-mediated 
DAT regulation as revealed by either trafficking or functional studies. We found 
that DAT 615C constitutively internalizes and recycles significantly faster than 
WT DAT. Moreover, unlike WT DAT, AMPH failed to accelerate the basal rate of 
endocytosis of the 615C variant. Like the A559V variant, which a displays similar 
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loss of AMPH action, DAT 615C displays hyperphosphorylation, possibly due to 
its demonstrated increase in CaMKII association. Additional studies that elucidate 
determinants of DAT C-terminus/CaMKII associations and utilize this information 
for functional and regulatory studies with the full length transporter should help 
clarify how CaMKII associations dictate DAT trafficking. 
 While investigating the underlying cause for the lack of AMPH action in 
DAT 615C, we uncovered a novel role of CaMKII in supporting DAT function, one 
that at present only manifests itself with the 615C variant. Previous studies report 
biphasic regulation of the transporter in response to AMPH. Immediately upon 
AMPH administration (seconds), AMPH has shown to increase DAT activity via 
recruitment of DAT to plasma membrane and over the period of time (minutes) 
reduce DAT activity by reducing cell surface expression (Johnson et al., 2005a). 
This increased DAT expression might be governed by CaMKII activity and 
perhaps WT transporters also use CaMKII to sustain DAT activity similar to that 
seen with DAT 615C, though perhaps not under the conditions I used in my 
experiments. CaMKII-mediated effects could be occurring very rapidly and as 
such might not be measurable with traditional methods employed in these 
studies. Nonetheless, the effects of CaMKII inhibition on this rapid phase of 
biphasic regulation of DAT will require further investigation. Another possible 
mechanism by which this effect on WT DAT might be masked is through protein-
protein interactions required to produce the effect of AMPH. Studies delineating 
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protein-protein interaction requirements need to be addressed in the future 
studies. 
 The rapid, constitutive trafficking of DAT 615C may be attributed to the 
transporterʼs reduced localization to GM1- and flotillin-1 rich membrane 
microdomains. These microdomains are known to be rich in cholesterol and 
extraction of membrane cholesterol has been shown to alter DAT function (Foster 
et al., 2008, Hong and Amara, 2010). As demonstrated by Adkins and 
colleagues, these microdomains likely restrict DAT surface mobility as well as 
reduce rates of endocytic trafficking (Adkins et al., 2007). Alternatively, the 
transporter can reside in membrane depleted of these raft components and here 
traffics largely via constitutive endocytosis and rapid recycling. Decisions 
dictating the localization and trafficking of DAT are dependent on sequences in 
the distal C-terminus of DAT, which we suspect involves 
phosphorylation/dephosphorylation reactions at T613 as well as protein-protein 
interactions that allow or limit the motility of a protein in the raft fraction. Our 
model has parallels with the differential trafficking of insulin-responsive (GLUT4) 
and nonresponsive (GLUT1) glucose transporters. GLUT4 and GLUT1 
equivalently support glucose uptake, but GLUT4 traffics through a limited 
capacity, regulated pathway whereas, GLUT1, traffics in the same cells through 
higher-capacity, constitutive mechanisms (Zorzano et al., 1997). Finally, we 
showed that DAT 615C could act dominantly and presence of a negative charge 
near DAT C-terminus could inhibit AMPH-mediated DAT regulation. 
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 As with DAT A559V, there remain many opportunities to expand the 
impact of our studies with the DAT 615C variant. Our studies clearly demonstrate 
accelerated endocytosis and recycling of DAT 615C through a pathway lacking 
regulation by AMPH treatment or PKC activation.  
 Importantly, we are currently ignorant of the endocytic pathway along 
which this rapid trafficking occurs. DAT is known to shuttle between plasma 
membrane and recycling endosomes in PC12 cells (Loder and Melikian, 2003) 
and in dopaminergic neurons (Rao et al., 2011). We have yet to explore the 
recycling compartments that support our findings from stable Flp-In HEK cells 
and thereby determine components of the regulated versus constitutive path. 
Rab 11, a member of Ras superfamily of monomeric G proteins, has been shown 
to support constitutive trafficking of DAT in N2A neuroblastoma cells (Furman et 
al., 2009b) and it would be important to examine the localization of DAT 615C in 
relation to this small G protein, for example via sucrose or Percoll gradient 
fractionations. However, since Rab 11 has been suggested to support AMPH-
mediated trafficking of NET (Matthies et al., 2010), a close relative of DAT, 
molecules other than Rab11 may play a role in the shift from a regulated 
trafficking pathway to one more consistent with constitutive trafficking. Possibly, 
the use of the term “constitutive” by Furman and colleagues was misused in 
simply referring to a basal recycling pathway, which may or may not provide for 
regulation. If DAT recycles in N2A cells via a pathway that can respond to AMPH 
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or PMA, then we could expect DAT 615C to recycle through a separate 
compartment, such as one defined by Rab8 (Furman et al., 2009b).  
 Another important aspect of our studies that requires further investigation 
is the link of CaMKII associations and DAT 615C hyperphosphorylation to 
intracellular Ca2+ alterations. Previous studies have shown that CaMKII binds to 
the DAT C-terminus and modulates AMPH-mediated DA efflux (Fog et al., 2006). 
Since my experiments revealed 1) that CaMKII exhibits an increased association 
with DAT 615C variant and 2) that CaMKII activity regulates DAT 615C function, 
it seems reasonable to question whether the chronic expression of the variant 
can lead to elevated basal Ca2+ levels. Using a calcium 3 assay kit (Molecular 
Devices), I obtained preliminary data that basal Ca2+ is elevated in cells 
expressing DAT 615C as compared to WT DAT transfected cells, whether using 
transient expression or in Flip-in HEK 293 stable cells. A more quantitative 
approach such as the use of the ratiometric dye Fura 2AM and transiently 
transfected cells could provide a more definitive answer to this question. 
 My studies with the DAT 615C variant revealed that this transporter could 
enter into an “inactive” state when present on the cell surface when CaMKII 
activity is pharmacologically inhibited. These findings raise the question as to the 
physiological significance of an inactive state, or whether the observations are an 
artifact of the transporterʼs mislocalization. Studies with platelet SERT have 
demonstrated that this transporter, when treated with phorbol esters to activate 
PKC, internalizes minutes after the transporter moves to a less active state 
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(Jayanthi et al., 2005). Similarly, our group recently showed that p38 MAPK 
controls the intrinsic activity of surface-resident NET and SERT proteins (Steiner 
et al., 2008). In contrast, data from previous DAT studies (Kahlig et al., 2005) are 
consistent with internalization of the transporter in an active form, though such a 
conclusion requires knowledge of whether DAT transient currents are modified in 
active versus inactive states. Recently, Amaraʼs group has demonstrated a state 
of lower activity in DAT that arises from cholesterol depletion. Possibly, our 
findings with DAT 615C reflect the relocation of DAT away from cholesterol-rich, 
flotillin-1 and GM-1 enriched membrane microdomains.  Additional biophysical 
studies are needed comparing the steady-state an transient currents of DAT 
615C vs. WT DAT. Regardless of the outcome, our findings clearly reveal a 
capacity of DAT to enter into inactive states and thus the further investigation of 
this process may provide a path to the development of novel strategies to reduce 
DAT activity for therapeutic benefit, as in ADHD. 
 We hypothesized that DAT 615C imparts a negative charge via formation 
of a thiolate with Cys substitution and that this charge, more so than the physical 
alteration of removing the Arg residue, blocks AMPH action. This hypothesis is 
supported by the finding that conversion of Arg to Glu also eliminated AMPH 
regulation, whereas neutral amino acid substitutions retained regulation.  
Although negative findings cannot be said to be conclusive, we were unable to 
demonstrate that other potential posttranslational modifications that occur on Cys 
residues such as palmitoylation or nitrosylation explain the lack of AMPH action 
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on the variant transporter (See Appendix Figure 37). We are currently employing 
LC/MS approaches to achieve a more definitive analysis of potential Cys 
adducts.   
 Finally, most of our studies with DAT 615C have been pursued to date in 
HEK 293 cells. Although these cells offer an excellent model for pharmacological, 
biochemical and electrophysiological studies, they clearly do not provide the 
same environment as found in native DA terminals. However, we did recapitulate 
the finding that DAT 615C lacks of AMPH-mediated regulation in transiently 
transfected noradrenergic CAD cell line. Studies using cultured DA neurons from 
DAT KO mice where WT DAT or DAT 615C have been virally expressed could 
offer important insights. Ultimately, studies using a DAT 615C knock-in mouse 
will be needed to validate our findings in a native setting in vivo. Such a model 
would of course also allow us to gather important data that the DAT 615C variant 
is causal in contributing to ADHD in the proband from which the variant was 
isolated. 
 In conclusion, our findings with the DAT A559V and R615C variants yields 
evidence that ADHD, the most commonly diagnosed childhood disorder, is 
enriched for penetrant DAT coding variants. Indeed, four of the known DAT 
coding variants identified to date derive from studies with ADHD subjects. 
Besides identifying phenotypes associated with naturally occurring DAT variation 
our studies suggest that mechanisms that do not provide flexibility in controlling 
extracellular DA may be a common feature of ADHD. DAT A559V can promote 
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increased extracellular DA via spontaneous, voltage-dependent DA efflux from 
cytoplasmic stores, thereby generating “noise” due to DA release outside of that 
provided by the highly regulated process of vesicular release. DAT 615C exhibits 
a disrupted localization to compartments that normally subserve the sensitive 
regulation of membrane proteins; it lacks the ability to be downregulated by PKC 
pathways (as well as AMPH), and displays ectopic CaMKII associations and 
phosphorylation. Together, these attributes suggest strongly that the normal 
dynamic range of DAT surface expression and function has been significantly 
limited. DA neurons transit between tonic and phasic patterns of excitation and 
DA release (Goto et al., 2007). The mechanisms by which DAT responds to the 
varying demands imposed on DA circuits are largely unknown. The study of 
naturally arising, disease associated DAT coding variants provides an important 
path to uncovering these mechanisms and also in penetrating the complexity of 
neuropsychiatric disorders linked to compromised DA signaling. 
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CHAPTER VII 
 
INTRODUCTION TO APPENDICES 
 
Further Characterization of DAT 615C-Associated Altered regulation 
In addition to the data presented in Chapters III and IV, which resulted in a 
publication, I have pursued additional studies with the goal of increasing our 
understanding of regulatory perturbations resulting from the DAT 615C variant. 
Although, these findings are not published, they have informed previous and 
ongoing efforts. 
APPENDIX A: Effect of PKCβ inhibition on AMPH-mediated reduction in DA 
uptake 
 APPENDIX B: Determination of ectopic palmitoylation due to the presence of 
cysteine 
APPENDIX C: Effect of NOS activators and NO scavengers on AMPH-mediated 
reduction in DA uptake  
APPENDIX D: Effect of Dynasore on DA uptake 
APPENDIX E: Development and validation of a fluorescent-based assay to 
monitor DAT function and AMPH-mediated substrate efflux 
APPENDIX F: Measurement of intracellular Ca2+  
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APPENDIX A: Effect of PKCβ inhibition on AMPH-mediated reduction in DA 
uptake 	  
Activation of PKC leads to significant downregulation of DA transport 
activity, as well as DAT internalization (Huff et al., 1997, Vaughan et al., 1997, 
Zhang et al., 1997, Zhu et al., 1997, Daniels and Amara, 1999, Loder and 
Melikian, 2003). An isoform of PKC, PKCβ, colocalizes with DAT in 
mesencephalic neurons (O'Malley et al., 2010b), and regulates AMPH-mediated 
DA efflux (Johnson et al., 2005b) as well as DAT trafficking (Chen et al., 2009). 
Furthermore, the PKCβ inhibitor (3-(1-(3-lmidazol-1-ylpropyl)-1H-indol-3-yl)-4-
anilino-1H-pyrrole-2,5-dione) restored AMPH-mediated DAT trafficking and 
normalized ADE produced by the A559V variant (Erica Bowton et al, manuscript 
in preparation). Since the A559V and R615C variants share a common property, 
the inability to be regulated by AMPH, we investigated whether PKCβ inhibition 
would restore AMPH-mediated reduction in DA transport by the R615C variant. 
Here we used the same inhibitor dose (300 nM) and time (30 min) that produced 
alterations with the A559V variant. As shown in Figure 35, AMPH treatment 
produced the expected reduction in DA uptake for DAT 615R without affecting 
uptake by DAT 615C. PKCβ inhibition completely rescued the AMPH-mediated 
reduction in DA uptake for DAT 615R whereas the antagonist did not restore DA 
uptake capacity of DAT 615C. This result, although somewhat surprising, points 
towards a differential contribution of intracellular signaling networks to produce 
the same endo-phenotype, lack of AMPH-mediated trafficking through both DAT 
615C and the A559V variant. The lack of response of DAT 615C to a PKCβ 
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inhibitor  may relate to the lack of sensitivity to the PKC activator PMA, whereas 
DAT A559V exhibits PMA sensitivity. These findings, along with the localization 
of DAT A559V to GM1-positive microdomains, indicates that localization to these 
microdomains is required for PMA-induced DAT internalization whereas 
suppression of AMPH-induced trafficking can occur whether or not DAT is 
localized to these compartments.  
 







































Figure 35 Effect of PKCβ  Inhibitor on AMPH-induced Reduction in DA Uptake: (A) AMPH 
(10 µM, 30 minutes) treatment caused a significant DA transport reduction in 615R (49±13% of 
control) while having no effect on DAT 615C (84±8% of control). Pretreatment with the PKCβ 
inhibitor (300 nM, 30 minutes) before AMPH (10 µM, 30 minutes) addition blocked AMPH-
mediated DA transport reduction in DAT 615R (AMPH (49±13%) vs. PKCβ inhibitor + AMPH 
(92±9%)) while DAT 615C showed non-significant reduction upon PKCβ inhibitor + AMPH 
treatment (AMPH (84±8%) vs. PKCβ inhibitor + AMPH (76±7%). Data were normalized to basal 
DA uptake of respective cell lines. Significant differences were calculated using Studentʼs t-test. 
(n=3, P<0.05). 
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APPENDIX B: Determination of Ectopic Palmitoylation Due to the Presence 
of Cysteine 	  
DAT undergoes multiple posttranslational modifications including 
glycosylation, ubiquitination, phosphorylation, and most recently identified 
palmitoylation (Patel et al., 1994, Foster et al., 2002, Li et al., 2004, Miranda et 
al., 2007, Foster and Vaughan, 2011). These posttranslational modifications 
regulate DAT activity as well as expression as discussed in Chapter I. Foster and 
colleagues show that rat DAT gets palmitoylated on residue C580, which is 
present on the junction of TMD 12 and the cytoplasmic C terminus, and possibly 
on one or more unidentified sites (Foster and Vaughan, 2011). Acute loss of 
palmitoylation is shown to impact DAT activity, without a change in surface 
expression, whereas chronic loss of palmitoylation leads to decreased DAT 
surface expression and increased degradation along with DAT activity alterations 
(Foster and Vaughan, 2011). A similar role of palmitoylation has not yet been 
shown for other neurotransmitter transporters. 
Because the R615C variant introduces a cysteine, I asked the question 
whether this would result in ectopic palmitoylation? As palmitoylation plays a 
significant role in protein targeting and may be involved in altering protein-protein 
interactions, I hypothesized that signaling perturbations seen with the R615C 
variant could be due to changes in the mutant transporterʼs palmitoylation status. 
The conventional way of identifying protein palmitoylation is via metabolic 
labeling using [3H]palmitic acid followed by IP, SDS-PAGE, and autoradiography. 
Due to the low beta emission of tritium, such efforts take several months to detect 
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the palmitoylated protein. Therefore, I decided to use a click-chemistry 
methodology that offers a quick and reliable way to detect DAT palmitoylation. I 
have described, in detail, this procedure in Chapter II. Briefly, the click-chemistry 
reaction utilizes a copper (I)–catalyzed azide-alkyne cycloaddition reaction 
followed by the Staudinger ligation with biotin-linked alkynes, and probe-modified 
proteins can be detected by streptavidin–horseradish peroxidase blotting (Martin 
and Cravatt, 2009). When we used this technique to detect changes in 
palmitoylation with the R615C variant, we did not find any significant increase in 
the palmitoylation levels of DAT 615C compared to the wildtype DAT (Figure 36). 
These data need to be replicated with additional controls like hydroxylamine 
treatment to remove palmitoylation and C580A mutant DAT to check the 
specificity of the technique. Nonetheless, the initial results indicate that the 
signaling alterations observed in the R615C variant are not due to altered 






















Figure 36 Determination of Ectopic Palmitoylation Due to the Presence of Cysteine: DATs 
were metabolically labeled with 17-ODYA and then immunoprecipitated. On the beads, click 
chemistry was used and the resulting product was subjected to SDS-PAGE and western blotting. 
The top blot shows the signal obtained from streptavidin HRP blot indicating similar palmitoylation 
between wildtype DAT and DAT 615C. The same membrane was stripped and re-probed with 
DAT antibody. The immunoblot shows equivalent expression of DAT 615R and DAT 615C. (n=1)    
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APPENDIX C: Effect of Nitrous Oxide Synthase (Nos) Activators and Nitric 
Oxide (No) Scavengers on AMPH-mediated Reduction in DA Uptake 	  
While searching for possible answers to the conundrum of local negative 
charge as a reason for a lack of AMPH action with DAT 615C, my attention was 
drawn to the possibility that nitrosylation could explain these findings. Intracellular 
cysteines can get nitrosylated by action of NO and thereby impart a partial 
negative charge on that residue (Nagahara et al., 2009). NET, a closely related 
transporter to DAT, has been found to be nitrosylated (Kaye et al., 2000). 
Nitrosylation of NET occurs on C351 in TMD7, a residue that is absent in human 
DAT. Functionally, nitrosylation of NET leads to significantly decreased uptake 
activity (Kaye et al., 2000), similar to DAT 615C that as shown above displays a 
significantly lower DA transport Vmax. Therefore, we decided to inhibit NOS, an 
enzyme required for NO production, thereby attempting to inhibit ectopic 
nitrosylation of DAT. Using two separate NOS inhibitors, S-ethylisothiourea (EIT) 
and S-isopropylisothiourea (IIT), I evaluated the effect of NOS inhibition on 
AMPH-mediated DA transport reduction. Treatment of stable cells expressing 
DAT 615R with EIT alone produced a significant reduction in DA uptake whereas 
IIT treatment alone did not affect DA uptake (Figure 37A). Neither inhibitor, when 
used alone, had any effect on DAT 615C activity suggesting a lack of ectopic 
nitrosylation (Figure 37). Interestingly, pretreatment with both EIT and IIT resulted 
in rescue of AMPH-mediated reduction in the DA transport from the DAT 615R 
cells (Figure 38). As mentioned before, AMPH action is dependent on CaMKII 
activity, and NO regulates CaMKII expression (Johnston and Morris, 1995), 
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suggesting AMPH action may also have an unappreciated NO dependency.. 
Pretreatment of both EIT and IIT did not produce any further decrease in DA 
uptake from the DAT 615C expressing cells (Figure 38).  Possibly, these data 
may reflect the fact that CaMKII is already associated at a higher level with DAT 
615C, leading to elevated basal transporter phosphorylation, and is not further 
stimulated by a NO-CamKII dependent manner. 
 
  
Next we asked whether promoting nitrosylation by addition of a NO donor 
would impact AMPH-mediated DA transport reduction. Addition of the NO donor 
S-nitroso-N-acetylpenicillamine (SNAP) did not affect basal DA uptake for either 
DAT 615R and the R615C variant (data not shown). Previous reports also 
indicate that the NO donor, SNAP, does not have any effect on DAT, but reduced 
NET activity as mentioned before (Kaye et al., 2000). Surprisingly, I found that 























































DAT 615R DAT 615C
A B
Figure 37 Effect of NOS Inhibition on DA Uptake: (A) Treatment with EIT produced a 
significant reduction in DA uptake for DAT 615R (69±9% of basal) without affecting the activity of 
DAT 615R (122±20% of basal). (B) IIT treatment did not produce any significant reduction in DA 
uptake for both DAT 615R (93±10% of basal) and DAT 615C (83±9% of basal).  
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had no effect on DAT 615C (Figure 39). Both NOS inhibition and treatment with a 
NO donor rescued the AMPH-mediated DA transport reduction in the wildtype 
DAT. These similar outcomes of supposedly opposite treatments raise the 
validity of use of these compounds and may need further characterization before 
arriving to a conclusion.   Alternatively, a possible explanation is that the NOS 
antagonist can block AMPH actions with DAT 615R because AMPH induces a 
Ca2+-NOS-CamKII dependent mechanism leading to transporter internalization. 
Thus, NOS blockade presents AMPH effects. When cells are pretreated with a 
NO donor, the need for AMPH-induced Ca2+ generation is no longer needed as 
the product of Ca2+ driven NOS activity is already provided. When AMPH is then 
added to these cells, no AMPH effect is seen because under basal conditions, 
the actions of AMPH have already been mimicked. These findings require that 
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A B
Figure 38 Effect of NOS Inhibition on AMPH-mediated Reduction in the DA Transport: Data 
is normalized to individual treatment controls for each cell line. (A, B) Treatment with AMPH 
produced a reduction in DA uptake for DAT 615R (65±4% of basal) without affecting DAT 615C 
(93±12% of basal). EIT pretreatment rescued the AMPH-mediated DA transport reduction in DAT 
615R (94±12% of EIT) without affecting DAT 615C (78±12% of EIT). IIT pretreatment also 
rescued the AMPH-mediated DA transport reduction in DAT 615R (90±13% of IIT) without 
affecting DAT 615C (84±16% of IIT). (n=2)  
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no basal effects of SNAP on DAT 615R were observed. In other models (cite 
synaptosome studies), SNAP does act to reduce wildtype DAT activity. Thus, 
further studies are needed to explore the complexity of NOS contribution to both 









































Figure 39 Effect of a NO Donor on AMPH-mediated Reduction in the DA Transport: Data is 
normalized to individual treatment controls for each cell line. Treatment with AMPH produced a 
reduction in DA uptake for DAT 615R (65±4% of basal) without affecting DAT 615C (93±12% of 
basal). SNAP pretreatment rescued the AMPH-mediated DA transport reduction in DAT 615R 
(107±6% of SNAP) without affecting DAT 615C (97±16% of SNAP). (n=2) 
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APPENDIX D: Effect of Dynasore on DA Uptake 
AMPH-induced, as well as β-PMA-mediated, DAT internalization has been 
shown to occur through clathrin-mediated mechanisms (Daniels and Amara, 
1999, Saunders et al., 2000). Clathrin-mediated endocytosis involves attachment 
of adaptor protein molecules to a membrane associated protein followed by 
formation of clathrin-coated pits by sequential addition of clathrin chains and 
invagination. Finally, clathrin-coated vesicles are pinched off from the membrane 
by action of the GTPase dynamin (Robinson, 1994). The role of dynamin is 
crucial for clathrin-mediated endocytosis, since an inactive K44A mutant of 
dynamin blocked the internalization of clathrin-coated vesicles (Damke et al., 
1994). Recently, a small molecule inhibitor of dynamin, Dynasore, was 
developed, that rapidly blocks formation of coated pits within minutes of addition 
(Macia et al., 2006). Dynasore inhibits the GTPase activity of dynamin in vitro 
(Macia et al., 2006). Since AMPH-mediated DAT internalization is supposed to 
be clathrin-dependent, I tested whether blocking clathrin-mediated internalization 
could rescue the AMPH effects on wildtype DAT. Based on the literature, I chose 
a Dynasore concentration of 20 and 40 µM (Macia et al., 2006) and monitored 
the effect of AMPH in a DA uptake assay. As shown in Figure 40 treatment with 
either 20 µM or 40 µM dynasore alone did not alter DA uptake in the cell line 
stably-expressing WT DAT. Treatment with AMPH alone caused a significant 
decrease in DA uptake. Surprisingly, pretreatment with Dynasore before AMPH 
caused a further reduction in DA uptake, rather than a rescue. It is evident from 
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my studies with the CaMKII inhibitor, KN-93, that the transporter can be 
inactivated on the surface. Therefore, it is possible that inactive transporters may 
be retained on the surface, thereby reducing uptake even though clathrin-
dependent internalization of the transporter is blocked. Due to these incongruent 
data, we decided not to pursue these studies, with the possibility of 





























































Figure 40 Effect of Dynasore on AMPH-mediated Reduction in the DA Transport: Wildtype 
DAT Flp-In™ HEK cells were used. Data was normalized to Vehicle treatment as 100%. 
Treatment with AMPH (10 µM, 30 min) alone caused a significant reduction in DA transport 
(78±4% of Veh). Treatment with dynasore alone (20 or 40 µM, 30 min) did not cause any 
significant reduction in DA uptake. Pretreatment with 20 µM or 40 µM dynasore before AMPH 
addition caused significant reduction in DA uptake (56±5% for 20 µM dynasore+AMPH and 
58±4% for 40 µM dynasore+AMPH). Significant differences were calculated using one-way 
ANOVA followed by Bonferroniʼs post hoc test. (n=4, P<0.01) 
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APPENDIX E: Development And Validation of a Fluorescent-based Assay 
to Monitor DAT Function and AMPH-mediated Substrate Efflux 	  
Historically DAT function has been monitored using [3H]DA uptake assays. 
Using radiolabeled DA, though more physiological, creates tritiated waste and 
limits extensive experimental manipulations due to the high cost associated with 
using radioactivity. Even more important, standard uptake assays do not permit a 
real-time assessment of transport kinetics, and they have the confound that the 
substrate, DA in this case, can activate cell-surface receptors during the transport 
assay (D2 receptors in this case). To circumvent these issues, in collaboration 
with Dr. Sandra Rosenthal, our lab developed fluorescent DAT substrates as 
molecules that can be monitored in real-time and easily adapted for high-
throughput screening of DAT function. 
 I have used one of these fluorescent compounds (IDT 307) to monitor the 
function of wildtype DAT and compared it to the function of DAT coding variants. 
The fluorescence of IDT 307 is not fluorescent in the extracellular medium. IDT 
307, similar to DA, uses DAT to enter the cell, and fluorescence intensity 
increases once transported inside the cell due to substrate immobilization on 
intracellular proteins. This increased fluorescence can be measured as a function 
of time using a kinetic fluorescence plate reader. The commercial form of IDT 
307 is available from the Molecular Devices as “Neurotransmitter Transporter 
Uptake Assay Kit”. 
 Saturation kinetic analysis using [3H]DA uptake assays using DAT 615C 
showed reduced DA transport Vmax without a significant change in Km (Chapter 
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III). I performed similar saturation kinetic analysis using IDT 307 and established 
decreased IDT 307 transport Vmax associated with the R615C variant (DAT 615R, 
32279±6110 vs. DAT 615C, 22079±2827 RFU/µg protein) (Figure 41). 
Interestingly, the affinity (KM) of DAT 615C for IDT 307 also appears to be 
increased (DAT 615R, 2.6±1.7 vs. DAT 615C 6.1±2.1 µM), possibly owing to 
structural differences between natural substrate, DA, and a synthetic substrate, 
IDT 307. These findings may point to D2 modulation of DAT to place the 
transporter in a high affinity state, which could be tested by studies using DA as a 
substrate in conventional transport assays +/- the D2 receptor antagonists 
haloperidol or sulpiride or by testing IDT307 uptake via fluorescence methods 
using the D2 receptor agonist quinpirole.  
 Next, I tested whether IDT 307 can be used to detect substrate efflux, 
similar to the DA efflux detected upon AMPH treatment. One thing to note here is 
that IDT 307 appears to need intracellular immobilization to show increased 
fluorescence intensity and this interaction may be strong enough to block the 
efflux of IDT 307 upon AMPH administration. Flp-In HEK stable cells lines were 
loaded with IDT 307 for 10 min, and excess IDT 307 was washed away before 
addition of AMPH. Change in fluorescence was measured and, as shown in 
Figure 42, AMPH did cause a detectible change in IDT 307-mediated 
fluorescence, whereas vehicle control and GBR 12909-treated cells showed a 
minimal decrease in the fluorescence (data not shown). I was also able to detect 
diminished IDT 307 efflux activity in the DAT 615C transfected cells as compared 
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to DAT 615R. These findings are consistent with the reduced surface expression 
of DAT 615C, but are at odds with the data previously reported for AMPH-
mediated DA efflux. These findings may reflect the role of the D2 receptor in 
maintaining the efflux of DA, despite reduced DAT 615C surface expression, an 
activity that IDT 307 will not produce.  Overall, these findings indicate that the use 
of IDT 307 provides a novel paradigm for studying DAT-dependent substrate 
efflux and receptor modulation of transport and efflux processes. 
  

























Figure 41 Saturation Kinetic Analysis Using IDT 307 Uptake: IDT 307 uptake Vmax and Km are 
expressed as RFU/µg protein/min and µM respectively. Km and Vmax values are expressed as ± 
SEM. Compared to DAT 615R; both Vmax and Km are significantly lower for DAT 615C. (n=4) 














Figure 42 AMPH-mediated IDT 307 Efflux: Flp-In HEK Stable lines expressing DAT 615R, and 
DAT 615C were preloaded with IDT 307 for 10 min and AMPH-induced IDT 307 efflux was 
measured. Both wildtype DAT and the R615C variant display significant reduction in fluorescence 
upon AMPH treatment, which may indicate IDT 307 efflux. DAT 615R may exhibit greater efflux 
compared to DAT 615C. (n=1) 
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APPENDIX F: Impact of DAT Mutation on Intracellular Ca2+ 
AMPH-mediated DA efflux is dependent on intracellular Ca2+. Chelation of 
Ca2+ using 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA) or 
thapsigargin blocked AMPH-mediated DA efflux measured by amperometry 
(Gnegy et al., 2004). The AMPH-induced increase in intracellular Ca2+ is thought 
to activate CaMKII and regulate DA efflux (Fog et al., 2006). The DAT 615C 
variant displays a normal AMPH-induced DA efflux, but also exhibits loss of 
AMPH-mediated downregulation. This prompted me to investigate levels of 
intracellular Ca2+ in our stable cell lines. Here I used a commercially available, 
single wavelength Ca2+ measuring dye (Calcium 3 Assay Kit, Molecular Devices) 
to determine relative Ca2+ levels between DAT 615R and 615C expressing cells. 
Under basal conditions, DAT 615C displayed a significantly higher intracellular 
Ca2+ compared to the WT DAT (Figure 43). Measurement of Ca2+ over a period 
of 10 min using FlexStation also showed a sustained increase in the basal Ca2+ 
levels in cells expressing DAT 615C (data not shown). Unfortunately, treatment 
with either AMPH or a Ca2+ ionophore, A23187, produced similar increases in 
both WT DAT and the R615C variant. There are a few caveats to using this type 
of single wavelength determination of Ca2+ levels. It is very difficult to determine 
absolute levels of Ca2+ concentration and variability between cell lines (size, 
volume and density) is not accounted in the estimate. To circumvent these 
problems, I also measured intracellular Ca2+ using a dual wavelength Fura 2AM 
dye. Fura 2AM, is a membrane permeable, Ca2+ sensitive dye, which when 
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excited at 340 nm shows increased fluorescence upon Ca2+ binding and at 380 
nm shows decreased fluorescence upon Ca2+ binding. The ratio between 340 
and 380 gives a better estimate for free intracellular Ca2+. Our instruments are 
unfortunately not sensitive enough to rapidly shift between the 340 and 380 nm 
excitation making it impossible to generate any usable data. Nonetheless, results 
obtained from the calcium 3 assay kit strongly indicate altered basal intracellular 
Ca2+  in our stable lines and as such further studies using single cell Ca2+ imaging 
might reveal interesting underlying phenotypes, which might be pertinent to loss 
of AMPH action on the R615C variant.  Should these findings be reproduced and 
validated, they would suggest that DAT 615C can elevate intracellular Ca2+, for 
which a mechanism would need to be elucidated. Possibilities include 1) DAT 
615C fluxes Ca2+ instead of Na+ under basal conditions,, 2) DAT 615C tonically 
depolarizes the host cell, leading to altered Ca2+ homeostasis, or 3) DAT interacts 



























Figure 43 Measurement of Intracellular Ca2+: Flp-In HEK stable lines were used to determine 
intracellular Ca2+ using calcium 3 assay kit. Compared to DAT 615R, the R615C variant displays 
significantly elevated basal intracellular Ca2+. Data is normalized to basal intracellular Ca2+ from 
DAT 615R as 100% and expressed as ± SEM. (n=3; Studentʼs t-test , P<0.001) 
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